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Abstract
Title: Relationship of Initial Symptoms and Differential Dementia Diagnosis in a
Memory Disorder Clinic Sample
Author: Eugenia Milroy Boozer, M.S.
Major Advisor: Frank Webbe, Ph.D.

Objective: The present study examines the consistency of differential dementia
diagnoses based on neuropsychological testing. The accuracy rate of clinical
diagnoses of various types of dementias, including Alzheimer’s disease, vascular
dementia, dementia with Lewy bodies, frontotemporal dementia, mixed dementia,
and others, were identified. In addition, other common diagnoses made through
neuropsychological testing such as mild cognitive impairment (MCI) and mood
disorder were examined as part of the overall analysis. Additionally, initial reported
symptoms of dementia were examined to analyze how these first complaints might
ultimately relate to a clinical diagnosis.
Method: The neuropsychological testing data were catalogued from participants
who received neuropsychological testing at the Memory Disorder Clinic, along
with initial chief complaint symptoms that were gathered from patients’ electronic
medical records.
Results: patients diagnosed as within normal limits (WNL) were most often placed
in the normal range across the board. For patients diagnosed with a mood disorder
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or MCI, they were most often in the normal range except for executive
functioning, motor processing, and learning and memory in which patients
diagnosed with MCI were placed in the borderline range. Patients diagnosed with
Alzheimer’s disease or dementia other were most often categorized as impaired in
all domains. When examining individual scores, patients diagnosed WNL
performed best on majority of tests, though scores were undistinguishable from
MCI or mood disorder on some measures. Patients diagnosed with a mood disorder
scored significantly worse than those diagnosed WNL on several measures,
suggesting a mood disorder has the potential to share neurocognitive patterns with
dementia. Overwhelmingly, patients diagnosed with Alzheimer’s disease (AD)
performed the worst on individual learning and memory tests, along with exhibiting
the largest phonemic/semantic split in the language domain. Secondary symptom
complaints of mood disorder was most often associated with clinical diagnosis of a
mood disorder, while secondary symptom complaints of behavior changes,
psychotic symptoms, gait problems, and tremors were most often associated with a
clinical diagnosis of dementia other.
Conclusion: This study highlights the importance of being consistent in making
clinical diagnoses based on overall patterns of scores and considering initial
symptom complaints to ensure differential diagnoses are carried out as accurately
as possible.
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1
Introduction
As the older adult population, meaning age 65 and older, continues to
increase in number in the coming years, the cognitive problems that afflict a large
number of them will become more of a public health concern. Dementia is the
general term for memory loss and other intellectual abilities severe enough to
interfere with daily life, and Alzheimer’s disease, the most common form of
dementia, currently affects 5.3 million Americans, 5.1 million who are age 65 and
older. By 2050, this number is expected to increase by 10 million as the baby boom
generation continues to enter this age bracket (Alzheimer’s Association, 2015).
Additionally, it is estimated that by the end of the year 2015, 473,000 new cases of
people age 65 and older will have developed Alzheimer’s disease (Alzheimer’s
Association, 2015). In 2012, Alzheimer’s disease was reported as the sixth leading
cause of death following heart disease, malignant neoplasms, chronic lower
respiratory disease, cerebrovascular disease, and accidents (Heron, 2015). For those
ages 65 and older, Alzheimer’s disease moved up to the 5th leading cause of death,
and for people ages 85 and older, it was the 3rd leading cause of death (Heron,
2015). In 2013, 84,767 people had Alzheimer’s disease listed as the official cause
death on death certificates (Alzheimer’s Association, 2015).
With such a large number of people dealing with a debilitating disease with
no known cure, steps to insure both early and accurate diagnosis become critical for
effective treatment planning, which may include introduction of medication to treat
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symptoms and/or community resources. In addition, it is important to take measure
to distinguish different types of dementia. Even though Alzheimer’s disease is the
most common form of dementia, several other diagnosable dementias, such as
vascular dementia, frontotemperal dementia, Lewy Body dementia, and mixed
dementias all have different presentations and affect different domains of cognition.
Because a truly accurate diagnosis of Alzheimer’s disease can only be made postmortem (Alzheimer’s Association, 2015), understanding the neuropathology and
neuropsychology of dementia becomes important in terms of making diagnosis of
dementia as accurate as possible while the person is still alive in order to provide
the best possible treatment.
The following review of past research will provide information about
clinical diagnosis of dementia, neuropathology of dementia in terms of various
criteria available, and neuropsychology of dementia as described by various
patterns of neuropsychological evaluations. The accuracy rates of diagnosis will be
examined as well as the heterogeneity of neuropathology as can be seen in mixed
dementias. Finally, descriptions of the East Central Florida Memory Disorder
Clinic and the Florida Brain Bank Program, where data for this project was
collected, will be provided in conjunction with summaries of past research
involving these data.

3
Review of the Literature
Alzheimer’s Disease (AD)
The most basic definition of Alzheimer’s disease is a degenerative disease
of the brain that causes problems with memory, thinking, and behavior that are not
considered a normal part of aging (Alzheimer’s Association, 2015). The initial
symptom most patients tend to notice is forgetfulness that is severe enough to
interfere with daily life. Examples of this would include becoming confused,
getting lost in familiar places, misplacing items, and having word-finding difficulty
(Alzheimer’s Association, 2015). Increasing age is the biggest risk factor for
acquiring Alzheimer’s disease. Most people are diagnosed at age 65 or older, and
as many as one third of people over the age of 85 have Alzheimer’s disease
(Alzheimer’s Association, 2015). There are also some genetic risk factors. This
means that those who have a parent, brother, or sister diagnosed with Alzheimer’s
disease are more likely to develop the disease than those who do not. The risk
increases if more than one family member has the illness. Having a risk factor does
not guarantee that someone will get the disease, but only increases the likelihood
(Alzheimer’s Association, 2015). Some risk genes have already been identified. For
example, the APOE-Ɛ4 gene was the first identified and still has the strongest
impact. The APOE-Ɛ2and APOE-Ɛ3 are also common risk genes. People who
inherit a copy of the APOE-Ɛ4 gene have an increased risk of developing
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Alzheimer’s disease, and those who inherit two copies have an even greater risk
(Alzheimer’s Association, 2015).
The life expectancy for someone diagnosed with Alzheimer’s disease is
typically four to eight years following diagnosis, but some people can live as long
as 20 years depending on other factors. The Alzheimer’s Association (2015)
recognizes different stages of the disease. Preclinical Alzheimer’s disease begins
many years before there are any behavioral symptoms. During the early stage, or
mild Alzheimer’s disease, the person may be able to still function independently
with some memory lapses, such as forgetting familiar words or the location of
every day objects. In the middle stage, or moderate Alzheimer’s disease, the person
may begin confusing their words, get frustrated or angry, and act in unexpected
ways. They may have difficulty expressing thoughts and doing routine tasks. This
stage is typically the longest. Finally, the late stage, or severe Alzheimer’s disease,
occurs when the individual has lost his or her ability to respond to the environment,
have a conversation, or control movement. At this point, he or she require 24-hour
care and become more vulnerable to life threatening infections such as pneumonia
(Alzheimer’s Association, 2015).
There is still much that needs to be learned about the precise biological
changes that cause Alzheimer’s disease, the individual differences in progression of
the disease, and how it can be prevented, slowed, or stopped (Alzheimer’s
Association, 2015). As mentioned before, subjective cognitive decline is one of the
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earliest warning signs and may be a way to better identify those who are at high
risk of developing Alzheimer’s disease.
Vascular Dementia (VaD)
The second most common cause of dementia after Alzheimer’s disease is
vascular dementia. Put simply, vascular dementia is a form of dementia brought on
by conditions that block or reduce blood flow to the brain, which deprives the brain
cells of oxygen and nutrients. Changes in thinking can occur suddenly following
strokes that block major brain blood vessels (Alzheimer’s Association, 2015). The
location, number, and size of brain injury determines whether dementia will result
from the stroke and how an individual’s thinking and functioning will be affected.
In a large retrospective autopsy study, pure vascular dementia was diagnosed in
10.8% of patients. Of these, 92% had hypertension-related pathology, 75% had a
history of strokes, and 52-58% had myocardial infarction and/or cardiac
decompensation (Jellinger & Attems, 2010). For vascular dementia, the initial
symptoms are likely to be impaired judgment or impaired ability to make decisions,
plan or organize (Alzheimer’s Association, 2015). Additionally, it has been found
that sleep disturbances may be predictive of increased cognitive decline and
incident of vascular dementia (Elwood, Bayer, Fish, Pickering, Mitchell &
Gallacher, 2010). The prevalence of vascular dementia increases with age until
about ago 90, and men appear to be more frequently affected than women
(Korczyn, Vakhapova & Grinberg, 2012; Middleton, Grinberg, Miller, Kawas
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&Yaffe, 2011; Leys, Henon, Mackowiak-Cordoliani & Pasquier, 2005; Leys,
Pasquier & Parnetti, 1998). Also, the mortality of patients with vascular dementia
surpasses that of Alzheimer’s disease (Korczyn, Vakhapova & Grinberg, 2012;
Kalaria, et al., 2008).
The main risk factors for vascular dementia are artherosclerotic disease,
abdominal obesity, insulin resistance, hypertension and dyslipidemia. Presence of
the APOE-Ɛ4 gene may increase the risk for cognitive decline following a stroke.
Diagnosis of vascular dementia is not as straightforward as other forms of dementia
given the possibility of co-morbid changes in the brain, multiple forms of
diagnostic criteria, and the reliance on imaging methods, which come with different
types of criteria for defining brain abnormalities (Korczyn, Vakhapova & Grinberg,
2012). Rather than a diagnosis of pure vascular dementia, most cases co-occur with
Alzheimer’s disease (Korczyn, Vakhapova & Grinberg, 2012; Alzheimer’s
Association, 2015) with reports in the literature indicating up to 73% overlap
between the two (Grinberg & Heinsen, 2010).
Frontotemporal Dementia (FTD)
Frontotemporal dementia (FTD) is an umbrella term referring to a group of
disorders caused by progressive cell degeneration in the brain’s frontal and/or
temporal lobes (Alzheimer’s Association, 2015). Memory and spatial ability is
typically spared in early stages of the disease (Kramer, Jurik, Sharon, Rankin,
Rosen, Johnson & Miller, 2003) and initial symptoms include distinct changes in
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personality and behavior, and may include difficulty producing or comprehending
language (Alzheimer’s Association, 2015). More specifically, individuals with FTD
may exhibit marked apathy, social withdrawal, and stereotypic behavior
(Shinagawa, Ikeda, Fukuhara & Tanabe, 2006). Examples of stereotypic behavior
include clock-watching, use of ritualized behavior, and preoccupation with
counting and numbers (Bozeat, Gregory, Ralph & Hodges, 2000). Because of the
apathy and/or aphasia presented, individuals with FTD may at first be
misdiagnosed with having a memory disturbance. As the disease progresses,
individuals typically experience problems related to behavior including loss of
insight, disinhibition, mood changes, mental rigidity, and changes in eating
behaviors (Shinagawa, Ikeda, Fukuhara & Tanabe, 2006). Most people diagnosed
with this form of dementia develop symptoms at a younger age, such as around 60
years (Alzheimer’s Association, 2015).
There are two main presentations of FTD, which include a progressive
change in personality along with executive dysfunction (frontal variant) and
progressive fluent aphasia coupled with breakdown in semantic knowledge
(temporal variant) also known as semantic dementia (Bozeat, Gregory, Ralph &
Hodges, 2000). Patients presenting with semantic dementia typically display more
mental rigidity and depression, while the frontal variant patients tend to be more
disinhibited. However, both types present as behaviorally very similar with the
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main difference being marked semantic deficits in the semantic form (Bozeat,
Gregory, Ralph & Hodges, 2000).
Social dysfunction including problems with emotion processing, profoundly
affect those with FTD. This can lead to failure in recognizing negative emotions,
such as anger, disgust, fear, and sadness. This problem is especially associated with
right hemisphere atrophy, particularly inferior and lateral parts of the temporal
lobe, right orbitofrontal cortex, and the amygdala. Another abnormal finding in
patients with FTD is “Theory of Mind” deficits, or problems with the ability to
attribute beliefs, desires, and intentions to others, along with self-referential
processing and empathy. One way to measure this dysfunction is through the
interpretation of sarcasm. In general, sarcastic statements are more difficult for
FTD patients to interpret, and in one study, performance was strongly influenced
by the ability to identify emotion, especially negative, from social interaction
(Kipps, Nestor, Acosta-Cabronero, Arnold & Hodges, 2009).
Lewy Body Dementia (DLB)
Dementia with Lewy bodies (DLB) is a form of dementia that leads to a
decline in thinking, reasoning, and independent function due to abnormal
microscopic deposits, called Lewy bodies, that damage brain cells. The trademark
initial symptom of this dementia is well-formed visual hallucinations, as well as
possible sleep disturbance, slowness and gait imbalance, or other Parkinsonian
movement features. It is common for those with DLB to have coexisting
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Alzheimer’s disease (Alzheimer’s Association, 2015). However, visual
hallucinations tend to be more characteristic of pure DLB (Rongve, Bronnick,
Ballard & Aarsland, 2010). Other features of DLB include memory impairment,
depression, and problem solving difficulty. Cognitive impairment and visual
hallucinations most often occur before the Parkinsonism, which suggests cortical or
forebrain changes may induce clinical signs earlier than changes in the brainstem
(Auning, et al., 2011). According to the literature, DLB accounts for an estimated
20% of all dementia cases (McKeith, et al., 2005). DLB and Parkinson’s disease
dementia (PDD) tend to overlap considerably both clinically and pathologically,
therefore, the term Lewy body dementia (LBD) encompasses both (Lippa, et al.,
2007). Parkinson’s disease (PD) results in problems with movement, such as
slowness, rigidity, tremor, and gait changes. In PD, alpha-synuclein aggregates
appear in the substantia nigra and are thought to cause degeneration of the nerve
cells that produce dopamine. As PD progresses, it often results in dementia
secondary to the accumulation of Lewy bodies in the cortex or the accumulation of
beta-amyloid and tau tangles, similar to Alzheimer’s disease (Alzheimer’s
Association, 2015).
Mixed Dementia
Considerable attention should be paid to the common occurrence of more
than one type of dementia pathology existing simultaneously. In fact, literature has
shown that about half of those diagnosed with dementia have evidence of more
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than one cause (Alzheimer’s Association, 2015). When this is the case, the patient
is diagnosed as having a mixed dementia. Although the individual presents with
abnormalities characteristic of more than one type of dementia occurring
simultaneously, he or she may be similar or indistinguishable from those with
Alzheimer’s disease or another dementia (Alzheimer’s Association, 2015). The
most common type of mixed dementia is Alzheimer’s disease combined with
vascular dementia, followed by Alzheimer’s disease with dementia with Lewy
bodies, and Alzheimer’s disease combined with vascular dementia and dementia
with Lewy bodies (Alzheimer’s Association, 2015). Past research has found
vascular dementia with dementia with Lewy bodies to be a much less common
form of mixed dementia (Alzheimer’s Association, 2015).
Accurately diagnosing individuals with various types of dementia becomes
difficult with the possibility of mixed dementia. For instance, differentiating
between Alzheimer’s disease, vascular dementia, and mixed dementia is
complicated both by symptom overlap and lack of well-defined diagnostic criteria
(Zekry & Gold, 2010). According to the literature, prevalence rates for mixed
dementia vary quite widely, anywhere from two to 60% (Zekry, Hauw & Gold,
2002; Jellinger, 2002). Another study found one third of Alzheimer’s disease
patients reached clinical criteria for a second type of dementia, either
frontotemporal or dementia with Lewy bodies. There was little overlap between
FTD and DLB (Piguet et al., 2009). Additionally, clinical testing, identification of
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biomarkers, and neuroimaging may all fail to distinguish pure Alzheimer’s disease
and vascular dementia from mixed dementia cases, especially when there are
microscopic infarcts only identified after autopsy (Zekry & Gold, 2010). The risk
factors for mixed dementia encompass the risk factors of all pathologies involved.
For example, for mixed dementia including Alzheimer’s disease and vascular
dementia, the vascular risk factors, such as hypertension, are particularly important
(Zekry & Gold, 2010).
Clinical Diagnosis of Dementia
Differentiating between different types of dementia in a clinical setting can
be a difficult task. To assist with making accurate diagnoses, clinical guidelines are
available as the result of a consensus of consortium of experts. For example,
beginning in 1983, the National Institute of Neurological and Communicative
Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related
Disorders Association (ADRDA) joined together to establish criteria for describing
the clinical diagnosis of Alzheimer’s disease. The final report was published in
1982 (McKhann, Drachman, Folstein, Katzman, Price & Stadlan, 1984). Across
multiple studies in the years following the initial report, these criteria have proven
to be reliable for the diagnosis of probable Alzheimer’s disease with a sensitivity of
81% and specificity of 70% (Knopman et al., 2001).
More recently, in 2011, experts met due to a need for criteria revision in
order to incorporate modern innovations in clinical, imaging, and laboratory
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assessment. They came to the agreement that the criteria should be flexible enough
to be used by general healthcare providers without access to neuropsychological
testing, advanced imaging, and CSF measures (McKhann et al., 2011). The criteria
was divided into the following sections: all-cause dementia, probable Alzheimer’s
disease dementia, probable Alzheimer’s disease with increased level of certainty,
possible Alzheimer’s disease dementia, probable Alzheimer’s disease dementia
with evidence of the Alzheimer’s disease pathophysiological process, possible
Alzheimer’s dementia with evidence of Alzheimer’s disease pathophysiological
process, and considerations related to the incorporation of biomarkers into
Alzheimer’s disease dementia criteria.
According to the NINCDS-ADRDA criteria (McKhann et al., 2011), allcause dementia is diagnosed when there are cognitive or behavioral symptoms that
interfere with the ability to function at work or at usual activities, represent a
decline from pervious levels of functioning and performing, and are not explained
by delirium or major psychiatric disorder. Cognitive impairment is detected and
diagnosed through a combination or history-taking from the patient and
knowledgeable informant and an objective cognitive assessment, either a “bedside”
mental status examination or neuropsychological testing. The cognitive or
behavioral impairment involves a minimum two of the following domains:
impaired ability to acquire and remember new information (symptoms include
repetitive questions or conversations, misplacing personal belongings, forgetting
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events or appointments, and getting lost on a familiar route) impaired reasoning
and handling of complex tasks, poor judgment (symptoms include poor
understanding of safety risks, inability to manage finances, poor decision-making
ability, inability to plan complex or sequential activities) impaired visuospatial
abilities (symptoms include inability to recognize faces or common objects or to
find objects in direct view despite good acuity, inability to operate simple
implements, or orient clothing to the body) impaired language functions (symptoms
include difficulty thinking of common words while speaking, hesitations, speech,
spelling, and writing errors) changes in personality, behavior, or comportment
(symptoms include uncharacteristic mood fluctuations such as agitation, impaired
motivation, initiative, apathy, loss of drive, social withdrawal, decreased interest in
previous activities, loss of empathy, compulsive or obsessive behaviors, socially
unacceptable behaviors).
As far as distinguishing between various types of dementia, some
recommendations have been made following the third Canadian Consensus
Conference on the Diagnosis and Treatment of Dementia (Robillard, 2007). For
probable Alzheimer’s disease dementia, it was noted that the NINCDS-ADRDA
criteria provided very good sensitivity, but at the expense of specificity. This
reflects the issue that there are(?) common features between different types of
dementia (Robillard, 2007).
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For vascular dementia, the common criteria utilized is the State of
California Alzheimer’s Disease Diagnostic and Treatment Center criteria (Chui et
al., 1992), the National Institute of Neurological Disorders and Stroke, and the
Association Internationale pour la Recherche et l’Enseignement en Neurosciences
(NENDS-AIREN) (Roman et al., 1993), the Hachinski Ischemic Score (HIS)
(Hachinski et al., 1975), and the criteria provided in the DSM-IV (American
Psychiatric Association, 2000). All of these criteria have poor sensitivity and high
specificity. The lack of sensitivity can be explained by considerable overlap
between vascular and Alzheimer’s disease dementia. The experts proposed a more
descriptive approach to the diagnosis of vascular dementia, which would take into
account the neuropsychological profile of dementia, neuroimaging, and vascular
risk factors (Robillard, 2007).
The sensitivity of dementia with Lewy bodies diagnosis has been the
subject of controversy (Litvan et al., 2003) due to original reports that stated the
presence of Lewy bodies in any distribution was sufficient for diagnosis (Kosaka,
1978; Kosaka, Yoshimua, Ikeda & Budka, 1983). Overall, diagnosis of dementia
with Lewy bodies has low sensitivity and high specificity (Robillard, 2007).
The original Lund-Manchester criteria for frontotemporal dementia has
been found to have low specificity (Robillard, 2007). These criteria are divided into
two major sections: clinical diagnostic features of frontotemporal dementia and
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neuropathological diagnostic features of frontotemporal dementia. The clinical
diagnostic features are further divided into the following categories: behavioral
disorders, affective symptoms, speech disorders, spatial orientation and praxis
preserved, physical signs, and investigations. Also included are supportive
diagnostic features, such as onset before 65, diagnostic exclusion features, and
relative diagnostic exclusion features. The neuropathological diagnostic features
are subdivided into “frontal lobe degeneration type”, “Pick type”, and “motor
neuron disease type”. For each of these, the criteria are organized into gross
changes, distribution of microscopic changes, microscopic characteristics of grey
matter, and microscopic characteristics of white matter. Finally, diagnostic
exclusion features are included for the neuropathological diagnostic features
(Englund et al., 1994).
The Third Canadian Consensus Conference approved several
recommendations for the diagnosis of dementia (Robillard, 2007). The first
recommendation made was that the diagnosis of dementia remains clinical given
the evidence of good diagnostic criteria currently in use. Further, the sensitivity of
clinical diagnosis for possible or probable Alzheimer’s disease based on the
NINCDS-ADRDA criteria remained high with low specificity, so they
recommended continued use of these criteria. They concluded that mild
Alzheimer’s disease could be diagnosed with a high degree of specificity when the
presenting clinical picture is one of memory impairment. The currently available
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vascular dementia diagnostic criteria have variable accuracy, therefore, an
integrative approach to vascular dementia diagnosis based on all available evidence
(history, vascular risk factors, physical exam, clinical course, neuroimaging, and
cognitive impairment pattern) is recommended. They recommended that dementia
with Lewy bodies should be diagnosed when this pattern of dementia occurs before
or concurrently with Parkinsonism, given the considerable overlap of the clinical
features of dementia with Lewy bodies and Parkinson’s disease dementia. Due to
the frequency of coexistence between Alzheimer’s disease and Lewy body
neuropathology, the experts noted that it is impossible at this time to propose
clinical guidelines that would separate the two diagnoses with high specificity.
Finally, for patients presenting primarily with progressive decline in language or
praxis, or prominent changes in behavior or personality, frontotemporal dementia
should be considered (Robillard, 2007).
CERAD Criteria
Another important step in improving accurate diagnosis of dementia was
the funding of the Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) in 1986. The purpose of this consortium was to develop standardized,
reliable, and valid assessments of AD for use for all AD centers established by the
National Institute on Aging (NIA), provide training in their use, and amass
CERAD-based data from carefully evaluated patients and controls (Fillenbaum et
al., 2008). CERAD consisted of three critical elements: an administrative core,

17
headed by the principle investigator, a methodology and data management center,
and a series of task forces. The neuropsychology measures chosen were recognized
as assessing cognitive functions implicated in AD. Considerable attention was
given to developing standardized procedures for administering and scoring
magnetic resonance imaging in AD and in modifying the protocol in response to
pre-testing. However, inter-rater agreement was overall disappointing and
ultimately not recommended (Fillenbaum et al., 2008). The CERAD guidelines
have been recommended by the autopsy committee of the College of American
Pathologists and form the basis for the consensus guidelines on the autopsy
diagnosis of dementia with Lewy bodies (Powers, 1995).
Since its creation in 1986, CERAD neuropathology criteria have been and
continue to be used in a substantial number of studies, both in the US and abroad.
An overview of publications that have used CERAD measures indicates that
CERAD has had two major effects. First, it has provided accepted standards for the
clinical, neuropyshcological, and neuropathologic diagnosis of AD and it has
provided validated, normed measures that have been broadly used and that permit
comparison across studies and settings. When compared to the NINCDS-ADRDA
criteria, the CERAD criteria are stricter regarding the duration of memory loss but
more lenient regarding older age. After the first 10 years of the CERAD, further
development of the neuropathology protocol ceased. As a consequence, the
Neuropathology Task Force was unable to modify the battery to more appropriately
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reflect changes seen with other dementias and to incorporate the use of appropriate
markers (Fillenbaum et al., 2008).
In a more recent study examining differential diagnosis of patients attending
a specialist early onset dementia clinic, researchers explored the usefulness of
measurements through an examination of the relationship between clinical and
pathological diagnoses in a consecutive series of patients who came to postmortem. In particular, they focused on the differentiation between early onset
degenerative dementia Alzheimer’s disease and FTD (Snowden et al., 2011). They
found the measurements of crucial importance in making a diagnosis were the
nature and time course of evolution of symptoms, the relative weighting of
physical, cognitive, and the behavioral symptoms, signs, and precise characteristics
of cognitive change. The results of this study indicated a strong concordance
between clinical diagnosis at the time of patients’ initial referral and ultimate
pathological diagnoses. This confirmed that pathological diagnosis can be predicted
on clinical grounds with a high degree of accuracy.
DSM Criteria
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
(DSM-5) (American Psychiatric Association, 2013) can serve as another guide
towards diagnosing dementia. The major change between the DSM-IV and the
DSM-5 was the introduction of Neurocognitive Disorders (NCD) as a category.
This change supported literature on the continuum of cognitive decline and efforts
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to diagnose NCD further upstream, before clinical manifestations of the dementia
syndrome occur through expansion of the diagnostic criteria to include mild NCD,
which correspond to Mild Cognitive Impairment (Chong & Sahadevan, 2005; Geda
& Nedelska, 2012). The revised DSM-5 sought to enable recognition of the
neurocognitive impairment as a focus of diagnosis and treatment even before
progression to functional impairment onset (Ganguli et al., 2011). Another
important change in the DSM-5 is that memory deficit was no longer requisite for
inclusion in the category of NCD, given the inclusion of attention, executive
function, language, perceptual-motor, and social cognition among any of the
cognitive domains that may be impaired, and specific emphasis that decline be
assessed clinically with standardized neuropsychological testing (Tay et al., 2015).
In a study by Tay et al. (2015) involving diagnosis of patients attending a
memory clinic, the frequency of dementia diagnoses among early symptomatic
patients increased by almost 40% with operationalization of the DSM-5 criteria for
major NCDs. A distinguishing feature of the DSM-5 relates to the specification and
definition of the implicated cognitive domains, with less restrictive inclusion of the
domains for which impairment has to be demonstrated to fulfill a diagnosis of
major NCD. The move toward dropping memory impairment as a requisite for
diagnosis of major NCD in DSM-5 was consistent with increasing recognition for
relative preservation of memory in non-AD dementias. This is further supported by
demonstrated impairment in only the nonamnestic domains among almost half of
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MCI patients who failed to qualify for DSM-IV dementia diagnosis but were
subsequently reclassified as major NCD with the DSM-5 criteria (Tay et al., 2015).
With several different ways to diagnose and classify dementia, it can be
difficult to decide which system to utilize. Domenech & Azpiazu (2015) suggest
that an individual can be characterized using one of three approaches: categorical,
dimensional, or a combination of both. A categorical approach is based on the
presence or absence of symptoms that satisfy certain criteria or not. The
dimensional approach also takes into account the degree in which symptoms are
present or absent, and a combination of both approaches allows diagnostic models
that use both representations in dimensions and categories, having a greater
predictive validity than either approach alone. It is suggested that future
classification approaches should adopt and incorporate significant and continuous
dimensions that can be conceptualized as diagnostic specifiers in terms of genetic
factors, neural substrates, biomarkers, background, personality traits, cognitive and
affective deficits, the development of the disorder, and the response to therapy
(Domenech & Azpiazu, 2015)
Neuropathology of Dementia
Alzheimer’s Disease
The two hallmarks of the neuropathology of Alzheimer’s disease are
neurofibrillary tangles and “senile plaques.” Other changes include amyloid
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angiopathy, brain atrophy, synaptic pathology, white matter rarefaction,
granulovacuolar degeneration, neuron loss, TDP-43 proteinopathy, and
neuroinflammation (Nelson et al., 2012). The pathologic processes underlying
sporadic Alzheimer’s disease include intraneuronal formation of abnormal tau
protein and extracellular deposition of β-amyloid protein (Nelson, Braak &
Markesbery, 2009). Alzheimer’s disease-related lesions develop at certain sites
within the brain and then progress according to a predictable sequence to other
areas. Intraneuronal lesions associated with Alzheimer’s disease occur before
puberty or in early young adulthood (Braak & Del Tredici, 2011). Therefore, the
earliest stages of Alzheimer’s disease may exist long before presentation of
cognitive symptoms.
Neurofibrillary tangles are found in almost every class of brain disease and
are universal in normal aging subjects. They are also considered a secondary
response to injury. Widespread neocortical neurofibrillary tangles are almost
always associated with severe cognitive impairment in more than one disease state
(Nelson et al., 2012). Neurofibrillary tangles are composed of abnormal fibrils
measuring about 10 nm in diameter that occur in pairs and wound in a helical
fashion with a regular periodicity of 80 nm (Kidd, 1963; Wisniewski, Narang &
Terry, 1976). The primary component of the neurofibrillary tangle is the
microtubule-associated protein tau, which is abnormally phosphorylated with
phosphate groups attached to specific sites on the molecule (Lee et al., 1991).
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For unknown reasons, vulnerable projection cells in the human brain begin
to produce an abnormally phosphorylated tau protein that does not bind to
microtubules and lies free, in high concentrations, in cytosol. Abnormal tau tends to
form nonbiodegradable aggregates, which accumulate intraneuronally and are
initially referred to as “pretangles”. This pretangle material can evolve into rigid
fibriolar and argyrophilic neuropil threads in dendritic processes and neurofibrillary
tangles in cell bodies (Braak & Del Tredici, 2012). Based on this process of
neurofibrillary tangles, the progression of Alzheimer’s disease has been divided
into six stages known as Braak and Braak staging (Braak & Braak, 1991). Stage I
consists of cortical neurons that are susceptible to Alzheimer’s disease that occupy
the laterally adjoining transentorhinal region of the temporal lobe. During stages I
and II, tau lesions are mainly localized within the entorhinal region of the temporal
lobe, particularly within the superficial entorhinal layer of medium-sized multipolar
neurons. In stage III, pathology is restricted to a few regions in medial portions of
the temporal lobe. In stage IV, most areas of the neocortex remain uninvolved.
Cortical pathology remains somewhat less extensive, but still severe in stage V, and
occurs when the individual is no longer in possession of a fully functional cerebral
cortex, and is nearly always demented. At this point, a clinical diagnosis of
Alzheimer’s disease is usually made. Finally, stage VI represents the end-stage of
Alzheimer’s disease when all cortical regions display severe lesions (Braak & Del
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Tredici, 2012). These stages were devised by mapping out the extent and
distribution of lesions in brain specimens with no clinical data available at the time.
Although not all Alzheimer’s disease patients progress precisely along these stages,
they do represent a useful concept and provide a format for neuropathologists to
use in evaluating the development of Alzheimer’s disease (Perl, 2010).
Senile plaques are extracellular deposits of β -amyloid peptides and are
found in high proportion in all elderly persons, but the subtype neuritic plaques are
more likely to be associated with cognitive impairment. These are complex
structures defined by the presence of a central core accumulation of a 4-kD protein
with a beta-pleated sheet configuration called BA4 (Masters et al., 1985;
Beyreuther & Master, 1990; Kang et al., 1987). Neurotic plaques are ABPs
surrounded by degenerating axons and dendrites that often contain
hyperphophorylated tau aggregates (Nelson et al., 2012). Tau lesions are present
from the beginning to end phage of Alzheimer’s disease (Braak & Del Tredici,
2012).
In addition to senile plaques, the BA4 protein also tends to deposit in the
walls of the cerebral cortical blood vessels, which can cause vascular amyloid
deposition, also known as congophilic angiopathy. When the degree of vascular
involvement is severe, tendency for spontaneous vascular rupture leading to a focal
accumulation of blood in the brain tissue can occur. These hemorrhages tend to
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occur in the white matter of the frontal and/or occipital poles, often small and
multiple, and may be microscopic in size (Perl, 2010).
When examining the autopsied brains of individuals diagnosed with
Alzheimer’s disease, both gross and microscopic changes can be viewed. Most
notably, these brains will demonstrate extensive and widespread distribution of
both neurofibrillary tangles and senile plaques. Grossly, Alzheimer’s disease brains
show at least a modest degree of cerebral cortical atrophy primarily in the
frontotemporal association cortex. Associated loss of brain tissue generally leads to
a symmetrical dilation of the lateral ventricles. Finally, there is significant atrophy
of the hippocampus with an associated selective dilation of the adjacent temporal
horn of the lateral ventricle. By using one of a variety of silver impregnation
staining techniques, such as the modified Bielschowski technique, neurofibrillary
tangles can be viewed (Perl, 2010). Many studies have confirmed a correlation
between the presence of senile plaques, neurofibrillary tangles, and cognitive status
antemortem. In more advanced Alzheimer’s disease, the neuroanatomic distribution
of neurofibrillary tangles correlates with the location at which the neurons die and
with the cognitive domains affected in the patients (Nelson et al., 2012).
Frontotemporal Dementia
Frontotemporal lobar degeneration (FTLD) is the pathological term for FTD
(Josephs et al., 2011). The term encompasses a heterogeneous group of diseases
that overlap in gross and histological features, all of which are associated with
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varying degrees of atrophy, neuronal loss, and gliosis of the frontal and temporal
lobes. There are three main proteins identified in the mechanism of
neurodegeneration in these diseases are microtubule associated protein tau, the
transactive response DNA binding protein of 43 kD (TDP-43), and the tumor
associated protein fused in sarcoma (FUS). The majority of FTLDs can be
subclassified into FTLD-tau, FTLD-TDP, and FTLD-FUS based on the
biochemical signature of the abnormally deposited protein (Josephs et al., 2011).
The behavioral variant of FTD (bvFTD) can be associated with many
different FTLD pathologies. For example, bvFTD associated with FTLD-TDP type
3 tends to have a typical age of onset and patients are not hypersexual, stereotypic
or hyperphagic. Presence of apraxia of speech is tightly associated with FTLD-tau
(Deramecourt et al., 2010; Josephs et al., 2006). The clinical syndrome of semantic
dementia has been found to be highly associated with FTLD-TDP type 2 pathology
and patients commonly present with aphasia associated with left anterior medial
temporal lobe atrophy (Chan et al., 2001; Mummery et al., 2000).
Up to 50% of bvFTD cases have some family history of FTD, which
suggests a strong familial aggregation within the FTLD spectrum of disorders
(Cerami et al., 2012). The most frequent genetic mutations of FTD involve
microtubule-associated protein tau (MAPT) and progranulin (GRN) genes both
associated with high phenotypic variability as well as newly identified large
hexanucleotide repeat expansion in the first intron of C9OFT72 mutation (Cerami
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et al., 2012). Though the clinical presentation in MAPT mutation carriers is mostly
consistent with bvFTD, with a mean onset in the 50s, primary progressive aphasias
and late age at onset have been reported. GRN occurs in about 5-10% of cases and
the age of onset along with clinical features is widely heterogeneous. For
C9ORF72, the most common clinical phenotype is bvFTD, which is also widely
heterogeneous, even within the same family. Mood and psychotic disorders have
been described among the clinical presentations of patients with this mutation
(Cerami & Cappa, 2013). A study that examined the characteristics of 32 patients
with mutations in the C9ORF72 gene of patients with clinical syndromes of FTLD
found a strong association of the mutation with psychotic symptoms such as
delusions, hallucinations, paranoid ideation, and disordered thinking (Snowden et
al., 2012). When diagnosing bvFTD, focal lobar atrophy on conventional brain
MRI or CT has a relevant role. In the beginning, patients usually present a focal
degeneration of pregenual anterior cingulate cortex (pACC) and frontoinsular
cortex. These represent the basic components of the social and emotional
processing network (Seeley et al., 2008). Further, metanalysis has shown prominent
regional gray matter loss in the anterior medial frontal cortex, extending to other
frontal regions, and in other brain areas such as insula and subcortical striatal
regions (Pan et al., 2012).
As the disease progresses, the degeneration becomes more evident based on
four anatomically definite bvFTD subtypes as described by Whitwell et al. (2009).
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The frontal dominant type is defined by the presence of medial and lateral frontal
lobe atrophy. The frontotemporal type has extended frontal and temporal lobe
atrophy. The temporal type is described as having predominant involvement of the
medial and lateral temporal lobe. Finally, the temporofrontoparietal type produces a
wide atrophic pattern involving the temporal lobes as well as the frontal and
parietal regions (Whitwell et al., 2009). Specific gene mutations may influence the
neuroanatomical pattern of atrophy seen in bvFTD, showing prevalent frontal
symmetric atrophy in MAPT and C9ORF72 mutated patients and asymmetric in
GRN mutation carriers (Whitwell et al., 2013). Additionally, microstructural
changes in white matter tracts within the frontal lobe or connecting frontal and
temporal brain regions have been reported in bvFTD (Zhang et al., 2009).
Lewy Body Dementia
As the name implies, Lewy body dementia (LBD) is neuropathologically
characterized by numerous Lewy bodies and neuritis, along with neuronal cell loss
in the central and autonomic nervous systems (Kosaka, 2014). Lewy bodies are
spherical, intracytoplasmic eosinophilic neuronal inclusions with a dense hyaline
core and clear halo (Hancock, 2012). They are composed of alpha-synuclein, a 149kDa protein encoded by the SNCA gene, the function of which is not well
understood (Kosaka, 2014). Additionally, Lewy bodies are made of ubiquitin, acrystalin, β -crystalin and various enzymes (Hancock, 2012). Lewy body dementia
pathology initiates in the brainstem and propagates upward to the cerebral cortex
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(Braak & Del Tredici, 2008). However, in the cerebral type of LBD, numerous
Lewy bodies have been found in the cerebral cortex in spite of only a few in the
brainstem nuclei, which suggests in these cases that the Lewy pathology occurs in
the cerebral cortex and propagates downward to the brainstem (Kosaka et al.,
1996). In some cases, Lewy pathology may also begin from Auerbach’s plexus of
the lower esophagus or the olfactory bulb (Wakabayashi et al., 1988; Sengoku et
al., 2008).
It is the relatively widespread presence of Lewy bodies that differentiates
LBD from other dementia syndromes at postmortem examination. Most gray matter
atrophy can be seen in the temporal, parietal, occipital lobes, and in the region of
the basal forebrain (Beyer et al., 2007; Burton et al., 2002; Sanchez-Castaneda et
al., 2009; Whitwell et al., 2007). There is relative preservation of temporal lobe
structures compared to subjects with Alzheimer’s disease (Barber et al., 2000)
along with relatively preserved whole brain volume that may be due to preservation
of synapse integrity and neuronal counts (Hancock, 2012). Early pathological
changes incur in the amygdala, alongside other limbic structures, and are now
considered to precede the more global cognitive changes (Braak et al., 2003).
Burton et al. (2012) conducted a study to examine the relationship between in vivo
MRI volumes and underlying neuropathology in autopsy-confirmed LBD cases.
They found a relationship between amygdala volume on MRI and the burden of
Lewy body-associated pathology. The researchers suggested it is possible the
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atrophy of the amygdala in LBD may be associated with visual hallucinations
(Burton et al., 2012).
Another common neuropathological feature of LBD is the loss of
dopaminergic neurons in the substantia nigra pars compacta that project to the
striatum (Schulz-Schaeffer, 2010). In a study investigating the influence of nigral
neuronal loss as well as nigral (α-synuclein, tau) and striatl (α-synuclein, tau and
amyloid β) pathology on striatal I-FP-CIT SPECT uptake in autopsy confirmed
cases of LBD, α-synuclein burden showed a trend towards a negative correlation
with the number of nigral neurons. This suggests a reduction of nigral neurons
occurs in LBD and indicates probability of I-FO-CIT SPECT in distinguishing
LBD from other forms of dementia such as Alzheimer’s disease (Colloby et al.,
2012).
Vascular Dementia
Vascular alterations that cause cognitive impairment are diverse and include
systemic conditions affecting global cerebral alterations involving cerebral blood
vessels, most commonly small size arterioles or venules. Considering the vital
importance of the cerebral blood supply for the structural and functional integrity
of the brain, it is not surprising that alterations in cerebral blood vessels have a
profound impact on cognitive function (Iadecola, 2013). The most common
neuropathological abnormalities are multiple infarcts and lacunae in subcortical
regions, mainly cerebral white matter and basal ganglia, strategic infarcts in the

30
thalamus and the hippocampus, and infarcts in frontier territories of large cerebral
blood vessels vulnerable to one-time episodes of cerebral hypoperfusion (Hauw, De
Girolami & Zekry, 2007; Jellinger, 2002; Jellinger, 2008; Love, Louis & Eillison,
2008). For example, high-grade stenosis or occlusion of the internal carotid arteries
is associated with chronic ischemia and can lead to cognitive impairment even in
the absence of ischemic lesions (Balestrini et al., 2013; Cheng et al., 2012;
Johnston et al., 2004). Stroke doubles the risk for dementia, and approximately
30% of stroke patients go on to develop cognitive dysfunction within three years
(Allen et al., 2011; Leys et al., 2005; Pendlebury & Rothwell, 2009).
Besides a single stroke, multiple infarcts caused by multiple arterial
occlusions over time are well known to impair cognition, sometimes referred to as
multi-infarct dementia (Iadecola, 2013). The most prevalent vascular lesions
associated with cognitive impairment are related to alterations in small vessels in
the hemispheric white matter (Jellinger, 2013). White matter damage resulting from
such lesions consists of vacuolation, demyelination, axonal loss, and lacunar
infarcts, and the expansion of white matter lesions correlates with the evolution of
the cognitive impairment (Maillard et al., 2012). These are commonly associated
with cardiovascular risk factors such as hypertension, diabetes, hyperlipidemia, and
smoking (Gorelick et al., 2011; Wardlaw et al., 2013). Additionally, vascular
injuries resulting from cardiac arrest, hypoxic encephalopathy, and anaesthesic
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accidents can be causative of acute global cerebral cortical damage and dementia
(Ferrer, 2010).
In addition, microscopic infarcts and hemorrhages are independent
predictors of cognitive dysfunction, but are commonly associated with other
vascular pathologies such as leukoaraiosis, lacunar infarcts, large infarcts, and
hemorrhage (Smith et al., 2012; van Norden et al., 2013). Cortical microbleeds are
frequently associated with cerebral amyloid angiopathy, whereas microbleeds in
deep regions tend to be associated with white matter disease secondary to vascular
risk factors (De Reuck, 2012; Park et al., 2013). One study by Strozyk et al. (2010)
found that as the severity of leukoencephalopathy increased, so did the risk of
causes of dementia, including vascular dementia. They also found large infarcts
were associated with antemortem clinical diagnosis of vascular dementia. This
suggests that accumulating macroscopic vascular pathology, regardless of type,
contributes to the diagnosis of dementia, and does so in the presence of other
neurodegenerative pathology. While cognitive correlates of cortical infarcts and
lacunes have been reported in demented and non-demented older adults, the
contributions of other types of vascular lesions, such as cerebral amyloid
angiopathy, leukoencephalopathy and microinfarcts, to cognitive impairment states
are less well known (Strozyk et al., 2010).
There is substantial evidence that white matter changes are related to
vascular disease. One hypothesis is that these changes are related to chronic
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hypoperfusion in the territory of small perforating arteries (O’Sullivan et al., 2002;
Markus et al., 2000). Cerebral microbleeds are radiological lesions due to small
collections of old blood products that have previously leaked from cerebral vessels
affected by small vessel pathologies, mainly lipohyaline degeneration or amyloid
angiopathy (Greenberg at al., 2009). Cerebral microbleeds are commonly found in
patients with vascular dementia, and are defined according to standard criteria
(Pettersen et al., 2008; Cordonnier et al., 2006). Cerebral microbleeds may
influence cognitive function through direct structural damage to surrounding tissue,
functional disturbances in surrounding tissue, or because of disturbed small vessel
reactivity and function (Werring, Gregoire & Cipolotti, 2010). In various studies,
cerebral microbleeds have been found in 85% of memory clinic patients (Seo et al.,
2007) and 65% of patients diagnosed with vascular dementia (Cordonnier et al.,
2006).
Some rare genetic mutations are also associated with vascular cognitive
impairment. The most common is CADASIL syndrome that is caused by a frame
shift mutation of Notch-3 that either creates or eliminates a cysteine residue
(Chabriat et al., 2009). Other hereditary pathologies include familial CAAs caused
by mutations or duplications of APP, the cerebral autosomal recessive arteriopathy
with subcortical infarcts and leukencephalopathy (CARASIL) caused by mutation
of the TGFB repressor HTRA1, the autosomal dominant retinal vasculopathy with
cerebral leukodystrophy caused by frame shift deletions in the exonuclease
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TREX1, and mutations of the COL4A1 gene encoding the type IV collagen alpha
1 chain (Frederico et al., 2012; Gorelick et al., 2011; Lanfranconi & Markus, 2010).
Neuropsychology of Dementia
Alzheimer’s Disease
Due to the difficulty of distinguishing among different types of dementia
pre-mortem, clinicians must rely on neuropsychological tests to assist with
diagnosis. Much research has been done, and continues to be conducted, to further
refine neuropsychological batteries. Through this research and clinical work,
certain patterns of test scores can help define certain types of dementia. Typically,
this type of research and diagnosis must be made using comprehensive,
standardized testing, as opposed to mental status testing or brief assessment
protocols. Otherwise, it may be too difficult to detect subtle cognitive differences
between groups (Walker, Meares, Sachdev & Brodaty, 2005).
For example, with Alzheimer’s disease, studies have shown that patients
with Alzheimer’s disease typically perform worse in the memory domain compared
to other types of dementia (Reed et al., 2007). In a study comparing healthy persons
with those with mild frontotemporal dementia and those with Alzheimer’s disease,
those with mild Alzheimer’s disease performed worse on tests of memory (Walker
et al., 2005). Again, another study found that patients with Alzheimer’s disease
were more impaired on tests of episodic memory when compared with patients who
had frontotemporal dementia (Diehl et al., 2005). Specifically regarding phonemic
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and semantic tests of language, studies have shown that patients with Alzheimer’s
disease typically perform worse on semantic measures (Rogers, Ivanoiu, Patterson
& Hodges, 2006). Therefore, with Alzheimer’s disease, performance on
neuropsychological testing typically shows a significant impairment in the memory
domain compared to other domains.
Vascular Dementia
The typical expression of vascular dementia is executive dysfunction,
manifested as impaired attention, planning, difficulties in complex activities, and
disorganized thought, behavior, or emotion. This applies mainly to patients with
subcortical white matter disease and frontal lobe lesions (Sachdev et al., 2004;
Nordlund et al., 2007). Cognitive changes following strokes depend on their
location. For example, slower reaction times are expected results of lesions in the
frontal lobes or subcortical damage affecting the cortico-basal ganglionic-thalamic
circuits (Korczyn, Vakhapova & Grinberg, 2012). Executive function is more
impaired in vascular dementia than in early AD, while memory encoding and
consolidation are more impaired in AD. In one study, on a letter-sequencing task
(LST), the vascular dementia group demonstrated greater difficulty on portions of
the LST thought to be more dependent on executive functioning, and had more
omission and commission errors during sequencing and recognition tasks. Finally,
vascular dementia patients had greater difficulty with the temporal aspects of
memory than patients with AD (Hampstead et al., 2010). However, another study
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found sizeable executive functioning and working memory impairment in patients
with mild-moderate AD and vascular dementia with no differences between the
disease groups (McGuinness, Barrett, Craig, Lawson & Passmore, 2010).
Neuropsychological tests indicate compromises in semantic memory, and
reveal difficulties in verbal fluency tasks, which also reflect problems in executive
functions (Pimentel, 2009). Findings reveal that VaD patients exhibit less
impairment in episodic memory than AD patients, but present greater degree of
impairment in attention, executive and motor functions. Compromise in phonemic
verbal fluency has also been observed in VaD, while individuals with AD show
deficits in semantic fluency. There is substantial overlap of cognitive alterations
among AD and VaD, although each dementia type has distinct distinguishing
characteristics (Pimentel, 2009).
No single test can distinguish mixed dementia from either vascular
dementia or pure AD, therefore, comparing the neuropsychological profile of
patients with vascular dementia, and those with AD show inconsistent differences
from one study to another (Laukka et al., 2004). Cognitive deterioration up to three
months after a stroke is consistent with vascular dementia (Roman et al., 1993)).
Subcortical vascular dementia patients may have slow mentation, as opposed to
memory decline, and fluctuating alertness is frequent in vascular brain disease.
There also may be abrupt deficits in language problems or behavioral changes, as
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opposed to a slow progression seen in other forms of dementia (Korczyn,
Vakhapova & Grinberg, 2012).
Frontotemporal Dementia
In a critical review of frontotemporal dementia, Hornberger and Piguet
(2012) report that episodic memory processing is relatively intact in FTD. Patients
with the subtypes of behavioral variant frontotemporal dementia (fvFTD) and
progressive non-fluent aphasia are reported to perform within normal limits on
standard memory tests. Relative intactness of episodic memory appeared to be a
useful diagnostic marker to distinguish early frontotemporal dementia from AD, in
which early episodic memory disturbance remains the most common clinical
feature. In the semantic dementia variant, a more complex picture emerges, with
preservation of some components of episodic memory, notably recognition-based
visual memory and recall of recent autobiographical events. Impaired performance
on verbal, but not visuospatial memory, tests, combined with a loss of semantic
knowledge, should raise the strong possibility of semantic dementia. Historical and
current evidence shows that some patients with FTD can have episodic memory
problems similar to AD, which can make a diagnostic distinction difficult,
particularly early in the disease course. Other features supportive of this diagnosis
include preservation of visual memory, particularly under forced-choice
recognition format and preserved memory for temporal information and for recent
autobiographical events. There is evidence that patients with behavioral variant
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FTD and AD can present with similar anterograde memory deficits on
neuropsychological testing (Hornberger & Piguet, 2012).
Delayed recall memory tests, in particular tests involving verbal material
(i.e., word lists), emerge as a good predictor of behavioral variant FTD and AD
diagnosis (Hornberger et al., 2010). In addition, one study found that patients with
FTD had higher numbers of rule violations on the Tower Test than patients with
AD and controls (Carey et al., 2008). Patients with FTD were also impaired on a
digit span task, and inhibition of dominant responses (Hornberger, Piguet, Kipps &
Hodges, 2008) and overall did poorly in the D-KEFS (Huey et al., 2009). Another
study found that patients with AD were characterized by relative significant deficits
with respect to the fvFTD group in short story, Rey figure, attentive matrices, and
street completion test. Early deficits in executive functions cannot exclude a
diagnosis of AD. Even though executive functions are routinely assessed in cases
of frontal lobe damage, this should not be the focus of differential diagnosis of AD
and fvFTD (Giovagnoli, Erbetta, Reati & Bugiani, 2008). The FTLD constellation
of disorders, and particularly in FTD, continue to be underdiagnosed and
misdiagnosed, despite being fairly common in presenile neurodegenerative
diseases. The role of neurocognitive testing for early diagnosis will likely be small,
in that FTD is fundamentally a behavior disorder, and cognitive deficits may be
difficult to document (Wittenberg et al., 2008).
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Dementia with Lewy Bodies
In one study, DLB patients were impaired in visuo-construction, praxis,
attention, executive function, and delayed recall (Metzler-Baddeley et al., 2010).
Overall, visuospatial abilities were more impaired in those with DLB, with a trend
toward relatively preserved memory (Rongve, Bronnick, Ballard & Aarsland,
2010). Additionally, the severity of deficits on tests of visuospatial ability,
specifically construction, predicts the rate of ensuring global cognitive decline for
patients with DLB, but not for patients with AD (Hamilton et al., 2008). Hamilton
et al. (2008) found that DLB patients who exhibited severe construction deficits at
baseline, declined rapidly over the subsequent two years. In addition, DLB patients
with early severe visuospatial deficits experienced a greater incidence of visual
hallucinations than those with less severe visuospatial deficits (Hamilton et al.,
2008). Because visual hallucinations are among the strongest diagnostic predictors
of DLB, the neuropsychological assessment of visual perceptual and constructional
functions is critical in suspected DLB, and its differentiation from AD (Oda,
Yamamoto & Maeda, 2009). The third report of the DLB consortium mentioned
that a double discrimination can help differentiate DLB from AD, with relative
preservation of confrontation naming and short and medium term recall as well as
recognition, and greater impairment on verbal fluency, visual perception, and
performance tasks (McKeith et al., 1996).
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In addition to problems in the visuospatial domain, other studies have
demonstrated a greater attentional impairment in DLB patients when compared to
AD patients. One study found DLB patients were significantly more impaired than
AD patients on all tests of attention and fluctuating attention (Ayre et al., 1998).
Another study found the deficits of attention became more pronounced with
increasing dementia severity, so these deficits should be interpreted within the
context of overall cognitive deficits (Ballard et al., 2001). Oda, Yamamoto, and
Maeda (2009) found through analysis of multiple research studies that both
neuropsychological and clinical observations strongly suggest that DLB patients
experience great difficulty in sustaining attention.
Mood Disorders
Because of the large prominence of patients being diagnosed with a mood
disorder (i.e., depression, anxiety, bipolar disorder), either as a primary diagnoses
or secondary to dementia, it is worth reporting how mood disorders can affect
neuropsychological outcomes. For example, Mukherjee and Rangasawami (2014)
found that patients with affective disorders were impaired across the board on
attention, executive functions, and learning and memory. More specifically, they
found that bipolar depressed patients performed the worst on verbal memory tasks,
and showed some impairment in non-verbal memory, attention, and executive
functions, when compared to normals. Finally, they found that most patients who
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had a recurrent depressive disorder performed poorly in sustained attention and
verbal learning and memory. Similarly, Sweeney, Kmiec and Kupfer (2000) found
bipolar patients in a mixed or manic phase displayed deficits in executive functions,
episodic memory, and spatial span performance. For depressed patients, they found
the deficits to be more restricted to episodic memory. Finally, through metaanalysis, many studies have identified deficits across a broad range of cognitive
functions in mania and depression, namely on measures of attention, executive
planning, memory, and psychomotor speed (Chamberlain & Sahakian, 2006).
Clinicopathologic Studies
The ultimate goal of clinicopathological studies is to better understand the
clinical and biologic importance of identified pathological features. The ideal
correlation would be a linear association between the following two discrete
entities: impairment of health, and severity of pathology (Nelson, Braak &
Markesbery, 2009). However, this correlation is not often obtained in practice, due
to various factors such as functional reserve capacity, biologic variation between
individuals in both protective and pathogenic pathways, and incomplete
understanding of the disease mechanisms. Following an extensive review of the
literature regarding clinicopathological studies in Alzheimer’s disease, Nelson,
Braak, and Markesbery (2009) found there to be a correlation of amyloid plaques
and cognitive decline. However, they pointed out that controversy exists about the
best way to calculate the extent of amyloid plaque pathology. Despite wide
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variations in study designs, certain points emerge consistently among the studies
about amyloid plaques. Compared with neurofibrillary tangles (NFTs), there is a
weaker direct correlation between the density of amyloid plaques and the severity
of cognitive decline. The amyloid plaque subtype that seems to correlate best with
the severity of cognitive decline is the neuritic plaque. Patterns seen in an aged
person’s brain seem to divide into three groups: 1) few plaques, few NFTs and no
cognitive impairment; 2) many plaques, few NFTs and no cognitive impairment;
and 3) many plaques, many NFTs and cognitive impairment (Nelson, Braak &
Markesbery, 2009).
Regardless of the staining or counting method, the correlation between
neocortical NFTs and antemortem cognitive decline is strong in studies that span
the clinical spectrum of Alzheimer’s disease. In the course of Alzheimer’s disease,
the development of NFTs follows a predictable pattern, which seems to correlate on
one hand with where neurons die, and on the other with the cognitive domains
affected in Alzheimer’s disease. Nelson, Braak, and Markesbery (2009) noted
several limitations found commonly with these types of studies: 1) the schema of
amyloid plaques and NFTs causing Alzheimer’s disease is oversimplistic and
incomplete, 2) athe density of NFTs on autopsy correlates with cognitive decline
severity, this does not prove that NFTs are directly neurotoxic, and 3) more
questions are raised about what induces the formation of amyloid plaques and
NFTs in the first place (Nelson, Braak & Markesbery, 2009).
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A single clinicopathological study utilized multivariable regression analysis
to yield a strong negative association between the Braak stages of NFTs and level
of cognitive function, which supports the idea that the regional distribution of NFT
accumulation is on a continuum that maps well to clinical status. Further, results
from this study demonstrated strong and independent contributions of both neuritic
plaques and NFTs to cognitive impairment over the entire clinical course of
Alzheimer’s disease. Finally, the data showed definitively that marked
neuropathologic changes of advanced Braak stage V/VI and frequent neuritic
plaques are nearly always associated with a clinically observed dementia (SerranoPozo et al., 2013).
Another study examining the accuracy of clinical diagnosis of Alzheimer’s
disease found pathological confirmation in patients with a clinical diagnosis
recorded in the NACC database to be 77.67%. The researchers who examined the
data discovered DLB was the dementia most commonly misdiagnosed as
Alzheimer’s disease. From a neuropathological point of view, it was most likely
that the presence of Lewy bodies was underreported, since staining with antibodies
against ubiquitin or alpha-synuclein was not a routine procedure during most years
of previous studies (Shim, Roe, Buckles & Morris, 2013). Continuing systematic
comparisons of the current criteria for the clinical and pathological dementia
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diagnoses are essential to clinical practice and research, and may lead to further
improvement of the diagnostic procedure.
In a study that utilized the same Memory Disorder Clinic and Brain Bank
data as the current study, Mahaney (2009) focused on the clinical accuracy with
emphasis on the implications of diagnostic overlap on accuracy rates. The
researcher found that Alzheimer’s disease was identified in about 50% of the cases,
and about 75% of the total sample was clinically diagnosed with AD. It was found
that about 25% of participants clinically diagnosed with AD had either disaffirming
or complicated pathology after autopsy evaluation. The overall sensitivity and
specificity of the diagnosis of AD was found to be 85% and 33%, respectively.
Mahaney (2009) also found, upon autopsy, significant Lewy body
pathology emerged in 16% of the total sample, despite having no participants being
clinically diagnosed with DLB. She found vascular dementia to be the third most
common dementia in this sample. With regard to initial complaints, it was found
that memory loss was common across all diagnostic categories, despite the findings
that many dementias do not include memory loss as an early symptom (Mahaney,
2009).
The East Central Florida Memory Disorder Clinic
The East Central Florida Memory Disorder Clinic (ECFMDC) is one of 15
designated memory disorder clinics statewide and covers a service area that
includes Brevard, Indian River, Osceola, Southern Volusia, and St. Lucie counties.
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The clinic is a collaborative effort between Health First Aging Institute and the
Florida Institute of Technology School of Psychology. The Memory Disorder
Clinic has a Board of Directors, a Clinical Advisory Committee, and a Research
Committee, which all provide governance, guidance, and direction to the not-forprofit agency, which is primarily funded through the State of Florida Department of
Elder Affairs (http://www.ecfmdc.org/).
The mission of ECFMDC is to provide the most effective evaluation for
diagnosis and treatment for Alzheimer’s Disease and related disorders, to provide
information to all members of the community affected by Alzheimer’s disease or
related disorders, and to support, educate and train both family and professional
caregivers in best practices related to memory disorders. The clinic’s professionals
providing service include a multi-disciplinary team that includes a geriatrician,
neuropsychologists, neurologist, psychiatrist, psychologist, social worker,
gerontologist, and Florida Institute of Technology School of Psychology doctoral
students. These professionals work together with the patient’s primary care
physician to provide the best quality of memory care.
Florida Brain Bank Program
The Florida Alzheimer’s Disease Brain Bank is a service and research
oriented network of statewide regional sites. The intent of the brain bank program
is to study brains of persons clinically diagnosed with dementia, and to provide
tissue for research after their deaths. Mt. Sinai Medical Center contracts annually
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with the State of Florida to operate the primary brain bank. Coordinators at
regional brain bank sites in Orlando, Tampa, and Pensacola assist in recruiting
participants, and act as liaisons between the brain bank and participants’ families.
Alzheimer’s Disease respite care program providers, memory disorder clinics, and
model day care programs also recruit brain bank participants. Families of
participants obtain two significant service benefits from the brain bank:
1. A diagnostic confirmation of the disease written in clear, understandable
terms; and
2. Involvement in variable research activities both inside and outside of
Florida.
Brain bank participants must be pre-registered, so families must plan ahead, as a
comprehensive application must be completed, and medical records must be
collected, especially from the neurologist or other specialists who made the initial
diagnosis. Upon the death of the patient, a final pathology report is provided to the
family, and the patient’s physicians and the brain issue becomes available to
researchers worldwide. The diagnoses are a critical piece of the family’s medical
history and will become more important as new treatments become available
(http://www.elderaffairs.state.fl.us/doea/BrainBank/index.php).
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Statement of Purpose
The first objective of this study is to identify how consistently diagnoses are
made based on patterns of individual scores, as indicated by previous research, on
participants who were seen for neuropsychological evaluation at the East Central
Florida Memory Disorder Clinic. Based on research completed by Mahaney
(2009), the main diagnoses given were Alzheimer’s disease, Vascular Dementia,
Dementia with Lewy Bodies, and Frontotemporal Dementia. Mixed dementia and
other diagnoses were examined as well. The importance of this objective is to
examine the impact of dementia with multiple neuropathological processes, and the
importance of accurate clinical diagnosis to align with certain treatment
interventions.
A similar objective of this study is to examine the overall broad patterns of
neuropsychological evaluation scores in a brief battery to observe how differential
diagnoses are made based on these patterns. Finally, this study will be reviewing
the earliest reported symptoms of dementia, and then analyzing how closely those
complaints predict a clinical diagnosis. Again, this information becomes useful
when formulating a treatment plan as early as possible.
Hypotheses
1. Neuropsychological domains identified as impaired will be different among
neuropathological diagnoses. Specific sub-hypotheses are as follows:
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a. Alzheimer’s disease group will show more impairment in memory
and language domains compared to others.
b. Additionally, semantic fluency will be more impaired than
phonemic fluency within the Alzheimer’s disease groups.
c. For the diagnoses categorized as dementia other, neuropsychological
impairments will be more pronounced in the domains of executive
functioning, attention, and visuospatial abilities.
d. The MCI group will have scores lower than WNL and mood
disorder in all domains.
e. Patients in the mood disorder category will perform worse than
those patients in the within normal limits category across domains.
2. Initial behavior complaint symptoms will differ among clinical
neuropsychological diagnoses. Specific sub-hypotheses are as follows:
a. Alzheimer’s disease group will show the greatest amount of memory
loss initial complaint symptom, based upon the typical clinical
course.
b. The dementia other group will show the greatest amount of changes
in personality and behavior, sleep, and psychotic complaints as the
initial symptom based upon the typical clinical course.
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c. The mood disorder group will show more changes in mood
complaints as the initial symptom (i.e., depression or anxiety).
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Method
Participants
A convenience sample of 983 participants referred to the East Central
Florida Memory Disorder Clinic for neuropsychological evaluation was selected
for the larger analysis of identifying correlations between domains of impairment
and clinical diagnosis, as well as correlations of specific test scores and clinical
diagnosis. Participants were self, family, or doctor-referred for evaluation and
treatment of various memory disorders. Participants involved in the current study
completed a brief neuropsychological evaluation and were given a diagnosis based
on a clinical case review.
The total sample (N = 983) included 422 males and 561 females ranging in
age from 39 to 95, with a mean age of 78.11 at the time of evaluation. Years of
completed education ranged from 3 to 22, with a mean of 13.70 years. Much of the
total sample identified as Caucasian descent (N = 895; 91%), followed by those of
African American descent (N = 49; 5%), Asian descent (N = 4; 0.4%), and Native
American descent (N = 14; 1.4%). Some participants selected “Other” as their race
(N = 16; 1.6%) or chose not to respond (N = 5; 0.5%). Of the total number of
participants, 25 (2.5%) identified as Hispanic ethnicity, while the majority
identified as Non-Hispanic (N = 897; 91.3%), Other (N = 3; 3%), or chose not to
respond (N = 58; 5.9%). See Figures 1 and 2 for distribution of race and ethnicity.
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Documentation of all demographic information was gathered from each participant
at the time of evaluation through self-report and/or patient chart.

Figure 1. Race

Caucasian (91%)

African American (5%)

Native American (1.4%) Other (1.6%)

Asian (0.4%)
No Response (0.5%)

Figure 2. Ethnicity

Hispanic (2.5%)

Non-Hispanic (91.3%)

Other (3.3%)

No Response (5.9%)

Clinical diagnoses for participants were determined at the time of case
reviews by a multi-disciplinary team composed of a neurologist, geriatrician, social
worker, neuropsychologist, and doctoral level psychometrists, based on evaluation
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scores, patient and informant history, medical evaluation, and neuroimaging. It
should be noted a percentage of patients in the study went on to receive reevaluations anywhere from six months to a year or more, following their initial
evaluation, and may have incurred a change in clinical diagnosis. However, patient
re-evaluations are not included in this study to avoid duplication of participants,
and due to the use of alternate subtests chosen for the testing battery.
All participants were included in the analysis investigating initial behavioral
characteristics based on data gathered from each patient’s electronic medical
record.
Procedure
The primary analysis included participants who completed a brief
neuropsychological battery of tests, and subsequently were given a clinical
diagnosis based on scores. All testing data were recorded and stored in an
electronic database for all patients, along with related demographic data and
diagnoses. Most scores obtained were either scaled scores, T-scores, or Z-scores
corrected for age and/or education level and sex. The testing battery used from
January 2011 until November 2013 consisted of the following: Controlled Oral
Word Association Test (COWAT); Multilingual Aphasia Examination (MAE)
Sentence Repetition; Trail Making Tests A and B; Symbol Digit Modalities Test
(SDMT); Cognitive Screening Test (CST); Victoria Stroop Test; Clock Drawing
Test (Free and Copy); Shepherd Serial List Learning Test; and the Executive
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Interview (EXIT – Brief Edition). After November 2013, the MackSF4, a brief
version of the Boston Naming Test, in which the patient must correctly identify 15
common objects, replaced the MAE Sentence Repetition test in the language
domain. The testing battery from January 2011 until December 2014 utilized the
Cognitive Screening Test (CST; Headminder, Inc.) for visual learning and memory,
at which time it was replaced with the Rey-Osterrieth Complex Figure test (ReyO). It was also at this time the Rey-O Copy task replaced the Clock Copy task in
the visuospatial domain. Finally, a select group of participants were given the
Boston Naming Test (BNT) in place of the MackSF4 if significant naming aphasia
was suspected. However, the BNT is not included in these statistical analyses due
to the small number of patients. See Appendix A for full descriptions of each test.
Patients’ clinical diagnoses were divided and coded into the following
categories: Within normal limits (WNL), mood disorder (based on primary
diagnosis of either depression, anxiety, or both), mild cognitive impairment (MCI),
probable Alzheimer’s disease, and dementia other. The “dementia other” category
was created to capture infrequently diagnosed dementia such as mixed dementia,
Parkinson’s disease dementia, dementia of undetermined etiology, vascular
dementia, dementia with Lewy bodies, and frontotemporal dementia. It was
necessary to combine these diagnoses into one category to increase statistical
power.
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Information about patients’ initial symptom complaints was gathered from
the first doctor’s visit note, and coded into the following categories: memory loss,
mood (based on mention of present anxiety, depression, or bipolar disorder), sleep
(described as REM sleep disorder, insomnia, or other sleep problems), gait (noted
as unsteady, frequent falls, or balance concerns), behavior (most often described as
aggressive or acting out behavior, inappropriate sexual behavior, or any other
behavior changes), psychotic (based on symptoms of psychosis such as
hallucinations or delusions), tremor, personality change (most often noted by a
family member), and weakness.
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Results
Because some testing scores are recorded as raw score not corrected for age
and education level, these factors were analyzed separately to examine any
differences in diagnoses directly related to age and education. Next, the effect of
gender on diagnosis for each diagnostic category was analyzed. Then overall
frequencies of diagnoses were examined and recorded, along with the relationship
of domain impairment and clinical diagnosis. The remaining results analyzed
differences of individual scores and clinical diagnosis, which were divided by
respective domains: language, attention and concentration, executive functioning,
motor-processing speed, visuospatial, and learning and memory. Finally, analyses
of initial patient complaint and clinical diagnosis were examined.
Age of Patients and Diagnosis
A one-way ANOVA was conducted to examine the relationship of patient
age at time of testing and diagnose, and this relationship was found to be
significant, F (4, 873) = 31.20, p <0.001. Bonferroni post-hoc test revealed no
significant difference in age between patients diagnosed WNL and those diagnosed
with a mood disorder, though patients diagnosed as WNL were significantly
younger than patients diagnosed with MCI, Alzheimer’s disease, and dementia
other. There was no significant difference in age of patients diagnosed with MCI
and those diagnosed with Alzheimer’s disease and dementia other. There was also
no significant difference in patients diagnosed with Alzheimer’s disease and
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dementia other. However, patients diagnosed with Alzheimer’s disease were
significantly older than patients diagnosed with WNL or a mood disorder. See
Table 1 for mean ages.
Table 1. Patient age
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
311
196

M
75.31
73.14
79.58
81.13
79.31

SD
7.90
9.20
6.52
6.71
7.30

df
4

F
p
31.20 <0.001

Years of Education and Diagnosis
A one-way ANOVA was conducted to examine relationship of years of
education and diagnosis, and this relationship was found to be significant, F (4,
873) = 4.08, p = 0.003. Bonferroni post-hoc test revealed patients diagnosed with
Alzheimer’s disease had significantly fewer years of education than patients
diagnosed as WNL and those diagnosed with MCI. No other significant differences
were found between groups. See Table 2 for mean years of education.
Table 2. Years of education
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
311
196

M
14.41
13.89
14.20
13.40
13.59

SD
2.48
2.17
2.72
2.80
2.93

df
4

F
4.08

p
0.003
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Sex and Diagnosis
A chi-square test was performed to examine broad relationships between
diagnostic category and sex. A significant difference was found between diagnosis
2
and patient sex, X (4, N = 878) = 33.59, p < 0.001, where more females than males
were diagnosed with WNL, a mood disorder, Alzheimer’s disease, and dementia
other. More males than females were diagnosed with MCI. See Table 3 for chisquare results of sex and diagnosis.
Table 3. Sex and diagnosis
Sex

WNL

Female Count 59
Expected 53.7
Male Count

35

Expected 40.3

Mood

MCI

AD

Dem. other

91

77

176

99

65.8

92.6

177.8

112.1

24

85

135

97

49.2

69.4

133.2

83.9

Clinical Diagnosis
Out of a sample of N = 878 included in the five diagnostic categories, the
most common diagnosis was Alzheimer’s disease with 31.6% (N = 311), followed
by dementia other with 19.9% (N = 196), then MCI with 16.5% (N = 162), mood
disorder with 11.7% (N = 115), and WNL with 9.6% (N = 94). See Table 4 for
percentages and frequencies of clinical diagnosis.
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Table 4. Clinical diagnoses
Diagnosis
Alzheimer’s Disease
Dementia Other
MCI
Mood Disorder
WNL

Frequency
311
196
162
115
94

Percent
31.6%
19.9%
16.5%
11.7%
9.6%

Clinical Diagnosis based on Domain
A chi-square test was performed to examine broad relationships between
diagnostic category and domain of impairment. A relationship was found between
2
diagnosis and level of impairment in the language domain, X (8, N = 877) =
192.13, p < 0.001, where patients diagnosed as WNL, a mood disorder, or MCI
performed most often in the normal range, and those diagnosed with Alzheimer’s
disease and dementia other were most often in the borderline range. See Table 5 for
chi-square relationships in the language domain.
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Table 5. Level of impairment in language domain and diagnoses
Diagnosis
WNL

Mood disorder

MCI

Normal

Borderline

Impaired

Total

N

78

14

2

94

%

19.6

4.6

1.2

10.7

N

80

30

5

115

%

20.1

9.8

2.9

13.1

N

102

50

9

161

%

25.6

16.3

5.2

18.4

91

127

93

311

%

22.9

41.5

43.8

35.5

N

47

85

64

196

%

11.8

27.8

37.0

22.3

Alzheimer’s disease N

Dementia other

There was also a relationship found between diagnosis and level of
2
impairment in the attention and concentration domain, X (8, N = 869) = 289.37, p
< 0.001, where patients diagnosed with WNL, a mood disorder, or MCI were more
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likely to be in the normal range, whereas those diagnosed with Alzheimer’s disease
and dementia other were more likely to score within the impaired range. See Table
6 for chi-square relationships in the attention and concentration domain.
Table 6. Level of impairment in attention and concentration domain and diagnoses
Diagnosis
WNL

Mood disorder

MCI

Normal

Borderline

Impaired

Total

N

85

8

1

94

%

23.6

3.4

0.4

10.8

N

80

22

13

115

%

22.2

9.4

4.7

13.2

N

92

57

13

162

%

25.6

24.4

4.7

18.6

76

92

138

306

%

21.1

39.3

50.2

35.2

N

27

55

110

192

%

7.5

23.5

40.0

22.1

Alzheimer’s disease N

Dementia other
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There was a relationship between diagnosis and level of impairment in the
2
executive functioning domain, X (8, N = 873) = 366.67, p < 0.001, where patients
diagnosed with WNL or a mood disorder were more likely to score in the normal
range, those diagnosed with MCI more likely to score within the normal or
borderline range, and those with Alzheimer’s disease or dementia other were more
likely to score within the impaired range. See Table 7 for chi-square relationships
in the executive functioning domain.
Table 7. Level of impairment in executive functioning domain and diagnoses
Diagnosis
WNL

Mood disorder

MCI

Normal

Borderline

Impaired

Total

N

84

9

1

94

%

29.7

3.2

0.3

10.8

N

74

29

12

115

%

26.1

10.2

3.9

13.2

N

70

73

19

162

%

24.7

25.7

6.2

18.6

41

108

160

309

%

14.5

38.0

52.3

35.4

N

14

65

114

193

%

4.9

22.9

37.3

22.1

Alzheimer’s disease N

Dementia other

There was also a relationship between diagnosis and level of impairment in
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2
the motor-processing domain, X (8, N = 871) = 253.21, p < 0.001, where patients
diagnosed with WNL or a mood disorder were more likely to score in the normal
range, those diagnosed with MCI more likely to score in the normal or borderline
range, and those diagnosed with Alzheimer’s disease or dementia other were more
likely to score in the impaired range. See Table 8 for chi-square relationships in the
motor-processing domain.
Table 8. Level of impairment in motor-processing speed domain and diagnoses
Diagnosis
WNL

Mood disorder

MCI

Normal

Borderline

Impaired

Total

N

81

12

1

94

%

21.7

5.0

0.4

10.8

N

84

19

12

115

%

22.5

7.9

4.7

13.2

N

91

58

13

162

%

24.3

24.1

5.1

18.6

85

94

128

307

%

22.7

39.0

50.0

35.2

N

33

58

102

193

%

8.8

24.1

39.8

22.2

Alzheimer’s disease N

Dementia other

Likewise, there was a relationship between diagnosis and level of
2
impairment in the visuospatial domain, X (8, N = 875) = 240.32, p < 0.001, where
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patients diagnosed with WNL or a mood disorder were more likely to score in the
normal range, those diagnosed with MCI were slightly more likely to score within
the normal range versus borderline range, and those diagnosed with Alzheimer’s
disease were more likely to score in the impaired range. Those diagnosed with
dementia other were likely to score in the borderline or impaired range. See Table 9
for chi-square relationships in the visuospatial domain.
Table 9. Level of impairment in visuospatial domain and diagnoses
Diagnosis
WNL

Mood disorder

MCI

Normal

Borderline

Impaired

Total

N

86

8

0

94

%

21.6

2.9

0.0

10.7

N

85

26

4

115

%

21.4

9.6

2.0

13.1

N

87

67

8

162

%

21.9

24.6

3.9

18.5

87

100

123

310

%

21.9

36.8

60.0

35.4

N

53

71

70

194

%

13.3

26.1

34.1

22.2

Alzheimer’s disease N

Dementia other

Finally, there was a relationship between diagnosis and the level of
2
impairment in the learning and memory domain, X (8, N = 876) = 794.76, p <
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0.001, where patients who were diagnosed with WNL or a mood disorder were
more likely to score in the normal range, those with MCI were most likely to score
in the borderline range, and those diagnosed with Alzheimer’s disease or dementia
other were more likely to score in the impaired range. See Table 10 for chi-square
relationships in the learning and memory domain.
Table 10. Level of impairment in learning and memory domain and diagnoses
Diagnosis
WNL

Mood disorder

MCI

Normal

Borderline

Impaired

Total

N

83

10

1

94

%

41.5

4.0

0.2

10.7

N

74

30

11

115

%

37.0

12.1

2.6

13.1

N

31

123

8

162

%

15.5

49.8

1.9

18.5

1

33

276

310

%

0.5

13.4

64.3

35.4

N

11

51

133

195

%

5.5

20.6

31.0

22.3

Alzheimer’s disease N

Dementia other

Language Domain
A one-way ANOVA was conducted to examine the differences between
diagnostic category for individual scores within each domain. For the language
domain, phonemic scores from the COWAT test differed significantly, F (4, 870) =
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29.21, p < 0.001. A Bonferroni post-hoc test revealed that patients diagnosed as
WNL had higher phonemic scores than those diagnosed with MCI (p = 0.43),
Alzheimer’s disease (p < 0.001), and dementia other (p <0.001). Further, patients
diagnosed with a mood disorder scored higher than those diagnosed with
Alzheimer’s disease (p < 0.001) and dementia other (p < 0.001). Similarly, patients
diagnosed with MCI also performed better than those diagnosed with Alzheimer’s
disease (p < 0.001) and dementia other (p < 0.001). Finally, patients diagnosed with
dementia other scored worse than patients diagnosed with Alzheimer’s disease (p <
0.001). See Table 11 for all mean scores.
Table 11. Phonemic scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
309
195

M
10.63
9.76
9.59
8.37
7.47

SD
2.87
2.38
2.75
2.81
3.03

df
4

F
p
29.21 <0.001

Regarding the semantic scores, there was a statistically significant effect for
diagnostic category, F (4, 873) = 123.35, p < 0.001. A Bonferroni post-hoc test
revealed patients diagnosed WNL had higher semantic scores than those diagnosed
with a mood disorder (p = 0.003), MCI (p < 0.001), Alzheimer’s disease (p <
0.001), and dementia other (p < 0.001). Patients diagnosed with MCI scored higher
than those diagnosed with Alzheimer’s disease (p < 0.001) and dementia other (p <
0.001). See Table 12 for all semantic mean scores.
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Table 12. Semantic scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
311
196

M
10.66
9.40
8.10
5.63
5.56

SD
2.55
2.48
2.43
2.57
2.45

df
4

F
p
123.35 <0.001

The difference, or split, between phonemic and semantic score was
examined, and there was a significant difference for diagnostic category, F (4, 873)
= 23.52, p < 0.001. A Bonferroni post-hoc test revealed patients diagnosed WNL
had a smaller split between scores compared to those diagnosed with MCI (p =
0.001), Alzheimer’s disease (p < 0.001), and dementia other (p < 0.001). Patients
diagnosed a mood disorder had a smaller split between scores compared to those
diagnosed with MCI (p = 0.015), Alzheimer’s disease (p < 0.001), and dementia
other (p < 0.001). Patients diagnosed with MCI also had a smaller split compared
to those diagnosed with Alzheimer’s disease (p < 0.001). Finally, patients
diagnosed with Alzheimer’s disease had a larger split in scores compared to
dementia other (p = 0.026). See Table 13 for mean split between phonemic and
semantic scores.
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Table 13. Phonemic/semantic split scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
311
196

M
-0.03
0.04
1.49
2.68
1.88

SD
2.67
2.72
3.00
2.98
2.99

df
4

F
p
23.52 <0.001

The MackSF4 score was found to differ across diagnostic categories, F (4,
477) = 13.34, p < 0.001. Because raw scores were utilized, patient age and years of
education were entered as covariates. Pairwise comparisons revealed patients
diagnosed WNL had higher scores than those diagnosed with Alzheimer’s disease
(p < 0.001) and dementia other (p < 0.001). Similarly, patients diagnosed with a
mood disorder and MCI performed better than those diagnosed with Alzheimer’s
disease (p < 0.001; p < 0.001) and dementia other (p < 0.001; p = 0.001). See Table
14 for MackSF4 mean scores.
Table 14. MackSF4 scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
49
42
68
198
127

M
13.45
13.19
12.69
10.75
11.30

SD
2.24
2.13
1.82
3.01
2.71

df
4

F
p
13.34 <0.001

Finally, the MAE Sentence Repetition Z-scores were examined and showed
a significant main effect for diagnostic category, F (4, 321) = 3.01, p = 0.02. The
Bonferroni post-hoc test revealed patients diagnosed WNL scored higher than those
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diagnosed with Alzheimer’s disease (p = 0.019). See Table 15 for MAE Sentence
Repetition mean scores.
Table 15. MAE sentence repetition scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
33
50
84
102
57

M
-0.10
-0.77
-0.65
-1.13
-1.08

SD
1.45
1.60
1.60
1.73
1.62

df
4

F
3.08

p
0.016

Attention and Concentration
A one-way ANOVA was conducted to examine differences between
diagnostic categories and individual testing scores within the attention and
concentration domain. For the Trails A test, there was a significant difference in
scores for diagnostic category, F (4, 860) = 45.19, p < 0.001. A Bonferroni posthoc test showed patients diagnosed WNL performed better than those diagnosed
with a mood disorder (p < 0.001), MCI (p < 0.001), Alzheimer’s disease (p <
0.001), and dementia other (p < 0.001). Patients diagnosed with a mood disorder
and MCI performed better than those diagnosed with Alzheimer’s disease (p <
0.001; p < 0.001) and dementia other (p < 0.001; p < 0.001) . Finally, those
diagnosed with dementia other performed significantly worse than those diagnosed
with Alzheimer’s disease (p = 0.005). See Table 16 for Trails A mean scores.
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Table 16. Trails A scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
160
304
192

M
10.39
8.28
8.13
6.57
5.53

SD
3.30
3.41
2.87
3.47
2.96

df
4

F
p
45.19 <0.001

For the Trails B test, there was a significant difference in scores for
diagnostic category, F (4, 846) = 98.41, p < 0.001. Patients who were diagnosed
WNL performed better than those diagnosed with a mood disorder (p < 0.001),
MCI (p < 0.001), Alzheimer’s disease (p < 0.001), and dementia other (p < 0.001).
Patients diagnosed with a mood disorder and MCI scored better than those
diagnosed with Alzheimer’s disease (p < 0.001; p < 0.001) and dementia other (p <
0.001; p < 0.001). See Table 17 for Trails B mean scores.
Table 17. Trails B scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
114
161
297
185

M
10.31
7.91
6.83
3.84
3.04

SD
3.21
4.11
3.88
3.66
2.99

df
4

F
p
98.41 <0.001

Regarding the SDMT Oral test, there was a significant difference in scores
for diagnostic category, F (4, 851) = 67.54, p < 0.001. According to the Bonferroni
post-hoc test, patients diagnosed WNL performed better than patients diagnosed
with a mood disorder (p = 0.024), MCI (p < 0.001), Alzheimer’s disease (p <
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0.001), and dementia other (p < 0.001). Patients diagnosed with a mood disorder
and MCI scored better than those diagnosed with Alzheimer’s disease (p < 0.001; p
< 0.001) and dementia other (p < 0.001; p < 0.001). See Table 18 for SDMT Oral
mean scores.
Table 18. SDMT oral scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
114
162
303
183

M
9.71
8.45
7.62
5.48
4.85

SD
2.83
2.91
2.80
3.15
2.99

df
4

F
p
67.54 <0.001

Analysis of the SDMT Written test revealed a significant difference in
scores for diagnostic category F (4, 854) = 42.08, p < 0.001. A Bonferroni post-hoc
test was conducted and it was found that patients diagnosed WNL performed better
than patients diagnosed with a mood disorder (p = 0.001), MCI (p = 0.007),
Alzheimer’s disease (p < 0.001), and dementia other (p < 0.001). Patients
diagnosed with a mood disorder and MCI scored better than those diagnosed with
Alzheimer’s disease (p < 0.001; p < 0.001) and dementia other (p < 0.001; p <
0.001). Finally, patients diagnosed with dementia other scored worse than those
diagnosed with Alzheimer’s disease (p = 0.030). See Table 19 for SDMT written
mean scores.
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Table 19. SDMT written scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
113
162
303
187

M
10.94
9.26
9.56
7.57
6.70

SD
2.85
3.26
2.80
3.23
3.29

df
4

F
p
42.08 <0.001

Executive Functioning
A one-way ANOVA was conducted to examine differences between
diagnostic categories and individual testing scores within the executive functioning
domain. It should be noted that Trails B scores are included in this domain as well
and results can be referenced above. For CST response accuracy scores, there was a
significant difference for diagnostic category, F (4, 501) = 29.82, p < 0.001. A
Bonferroni post-hot test was conducted and it was found that patients diagnosed as
WNL performed better than those diagnosed MCI (p < 0.001), Alzheimer’s disease
(p < 0.001), and dementia other (p < 0.001). Also, patients diagnosed with a mood
disorder performed significantly better than those diagnosed with MCI (p < 0.001),
Alzheimer’s disease (p < 0.001), and dementia other (p < 0.001). Finally, patients
diagnosed with MCI had better scores than those diagnosed with Alzheimer’s
disease (p = 0.004) and dementia other (p = 0.001). See Table 20 for CST response
accuracy mean scores.
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Table 20. CST response accuracy scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
64
86
118
143
95

M
8.28
8.12
6.27
4.98
4.66

SD
2.77
2.93
3.18
2.95
2.72

df
4

F
p
29.82 <0.001

With regard to the VST interference scores, a significant difference was
found for diagnostic categories, F (4, 824) = 4.13, p = 0.003. Patients diagnosed as
WNL performed better than those diagnosed with Alzheimer’s disease (p = 0.020)
and dementia other (p = 0.001). See Table 21 for VST interference score means.
Table 21. VST interference scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
112
158
292
173

M
11.10
10.10
10.15
9.84
9.36

SD
2.86
2.98
3.28
3.73
3.59

df
4

F
4.13

p
0.003

For VST words scores, there was a significant difference found for
diagnostic category, F (4, 837) = 32.75, p < 0.001. After a Bonferroni post-hoc test
was conducted, it was found that patients diagnosed as WNL performed better than
those diagnosed with a mood disorder (p = 0.003), MCI (p < 0.001), Alzheimer’s
disease (p < 0.001), and dementia other (p < 0.001). Patients diagnosed with a
mood disorder and MCI had better scores than those diagnosed with Alzheimer’s
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disease (p < 0.001; p < 0.001) and dementia other (p < 0.001; p < 0.001). See
Table 22 for VST word score means.
Table 22. VST word scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
113
161
295
179

M
9.21
7.96
7.65
6.50
6.21

SD
2.93
2.83
2.36
2.35
2.22

df
4

F
p
32.75 <0.001

Analysis of VST color scores revealed a difference for diagnostic category,
F (4, 828) = 40.63, p < 0.001. Following a Bonferroni post-hoc test, it was shown
that patients diagnosed WNL performed better than those diagnosed with a mood
disorder (p = 0.002), MCI (p < 0.001), Alzheimer’s disease (p < 0.001), and
dementia other (p < 0.001). Patients diagnosed with a mood disorder and MCI had
better scores than those diagnosed with Alzheimer’s disease (p < 0.001; p < 0.001)
and dementia other (p < 0.001; p < 0.001). See Table 23 for VST color score
means.
Table 23. VST color scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
113
159
292
175

M
10.57
9.10
8.23
7.04
6.71

SD
2.81
3.08
2.74
2.77
2.92

df
4

F
p
40.63 <0.001
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The Exit total raw scores were examined using age and years of education
as covariates. Exit scores are interpreted as lower scores indicating better
performance. Following analysis of these scores, a significant difference was
revealed for diagnostic category, F (4, 871) = 67.57, p < 0.001. Pairwise
comparisons showed the patients diagnosed as WNL performed better than those
diagnosed with MCI (p = 0.001), Alzheimer’s disease (p < 0.001), and dementia
other (p < 0.001). Patients diagnosed with a mood disorder and MCI had better
scores than those diagnosed with Alzheimer’s disease (p < 0.001; p < 0.001) and
dementia other (p < 0.001; p < 0.001). Table 24 for Exit score means.
Table 24. Exit scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
311
196

M
3.88
5.06
6.07
9.90
9.68

SD
2.33
2.91
2.73
4.33
4.41

df
4

F
p
67.57 <0.001

Motor Processing Speed
A one-way ANOVA was conducted to examine the differences between
diagnostic categories and individual testing scores within the motor processing
speed domain. It should be noted that Trails A, Trails B, SDMT Oral, and SDMT
Written scores are included in this domain as well and results can be referenced
above. Analysis of CST Response Speed scores revealed no significant differences
for diagnostic category, F (4, 499) = 1.76, p = 0.14.
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With the VST Dots score, there was found to be a significant difference for
diagnostic category, F (4, 832) = 31.72, p < 0.001. A Bonferroni post-hoc test was
conducted and revealed that patients diagnosed WNL performed better on this test
than those diagnosed with MCI (p < 0.001), Alzheimer’s disease (p < 0.001) and
dementia other (p < 0.001). Patients diagnosed with a mood disorder had better
scores than those diagnosed with MCI (p = 0.014), Alzheimer’s disease (p < 0.001),
and dementia other (p < 0.001). Finally, patients diagnosed with MCI performed
better than those diagnosed with Alzheimer’s disease (p = 0.001) and dementia
other (p = 0.006). See Table 25 for VST dots score means.
Table 25. VST dot scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
92
113
160
293
179

M
9.83
8.92
7.76
6.60
6.65

SD
3.23
3.08
2.82
2.94
2.83

df
4

F
p
31.72 <0.001

Visuospatial Ability
A one-way ANOVA was utilized to analyze the differences between
diagnostics categories and individual testing scores within the visuospatial domain.
Analysis of the Rey-O figure copy scaled scores revealed a significant difference
for diagnostic category, F (4, 114) = 5.95, p < 0.001. Following a Bonferroni posthoc test, it was found that patients diagnosed with a mood disorder scored better
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than patients diagnosed with Alzheimer’s disease (p = 0.001). See Table 26 for
Rey-O figure copy score means.
Table 26. Rey-O figure copy scaled scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
4
11
12
59
33

M
9.50
9.36
7.33
3.86
5.45

SD
2.08
3.61
3.23
4.24
4.77

df
4

F
5.95

p
<0.001

A portion of patients had Rey-O figure copy scores recorded as percentages
which were later coded based on percent ranges where lower percent is indicative
of greater impairment. A chi-square test was performed to examine broad
relationships between diagnostic category and percent range of impairment. A
relationship was found between diagnosis and level of impairment in the language
2
domain, X (16, N = 214) = 55.41, p < 0.001, where patients diagnosed as WNL
and with a mood disorder had a much higher percent of patients scoring in the
>16% range, and patients diagnosed with Alzheimer’s disease or dementia other
had a higher percent scoring in the <1% range. See Table 27 for chi-square results
for Rey-O figure copy percent impairment.
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Table 27. Rey-O figure copy percent impairment
Diagnosis
WNL

Mood

MCI

AD

>16%

11-16%

6-10%

2-5%

<1%

1

0

1

0

% 23.1

10.0

0.0

5.9

0.0

N

1

0

1

0

% 13.5

10.0

0.0

5.9

0.0

N

1

1

4

7

% 16.3

10.0

14.3

23.5

9.2

N

5

5

9

38

50.0

71.4

52.9

50.0

2

1

2

31

20.0

14.3

11.8

40.8

N

24

14

17

35

% 33.7
Dem. other N

14

% 13.5

The free clock total raw scores were examined using age and years of
education as covariates. Following analysis of these scores, a significant difference
was revealed for diagnostic category, F (4, 868) = 49.62, p < 0.001. Pairwise
comparisons showed patients diagnosed WNL performed better than those
diagnosed with MCI (p = 0.009), Alzheimer’s disease (p < 0.001), and dementia
other (p < 0.001). Patients diagnosed with a mood disorder and MCI had
significantly higher scores than those diagnosed with Alzheimer’s disease (p <
0.00; p < 0.001) and dementia other (p < 0.001; p < 0.001). See Table 28 for free
clock score means.
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Table 28. Free clock scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
114
162
311
194

M
9.39
8.59
8.18
5.78
6.24

SD
0.87
1.96
1.85
3.15
2.96

df
4

F
p
49.62 <0.001

Similarly, for the copy clock raw scores, age and years of education were
used as covariates. Analysis of these scores revealed a significant difference for
diagnostic category, F (4, 554) = 11.72, p < 0.001. Pairwise comparisons showed
patients diagnosed WNL, with a mood disorder, and MCI score significantly higher
than those diagnosed with Alzheimer’s disease (p < 0.001; p < 0.001; p = 0.002)
and dementia other (p < 0.00; p < 0.001; p < 0.001). See Table 29 for copy clock
score means.
Table 29. Copy clock scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
65
91
123
164
118

M
9.69
9.51
9.33
8.59
8.46

SD
0.58
1.00
1.00
1.89
2.01

df
4

F
p
11.72 <0.001

Learning and Memory
A one-way ANOVA was conducted to examine differences between
diagnostic categories and individual testing scores within the learning and memory
domain. Scores from the CST Learning portion were examined and there was a
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statistically significant difference for diagnostic category, F (4, 491) = 62.26, p <
0.001. A Bonferroni post-hoc test revealed patients diagnosed as WNL had higher
scores than those diagnosed with MCI (p = 0.001), Alzheimer’s disease (p < 0.001),
and dementia other (p < 0.001). Patients diagnosed with a mood disorder and MCI
performed significantly better than those diagnosed with Alzheimer’s disease (p <
0.001; p < 0.001) and dementia other (p < 0.001; p < 0.001). See Table 30 for CST
Learning score means.
Table 30. CST learning scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
63
85
119
133
96

M
11.24
9.64
9.22
4.69
5.64

SD
3.08
3.69
3.49
3.34
3.64

df
4

F
p
62.26 <0.001

CST Delay scores were examined and there was a statistically significant
difference for diagnostic category, F (4, 508) = 90.36, p < 0.001. A Bonferroni
post-hoc test revealed patients diagnosed WNL performed better than those
diagnosed with MCI (p < 0.001), Alzheimer’s disease (p < 0.001), and dementia
other (p < 0.001). Finally, patients diagnosed with a mood disorder and MCI
performed significantly better than those diagnosed with Alzheimer’s disease (p <
0.001; p < 0.001) and dementia other (p < 0.001; p < 0.001). See Table 31 for CST
Delay score means.
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Table 31. CST delay scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
63
86
119
145
100

M
10.56
9.57
8.44
3.60
4.59

SD
2.62
3.79
3.32
2.96
3.46

df
4

F
p
90.36 <0.001

A subset of patients was given Rey-O Immediate scaled scores which were
examined and there was a statistically significant difference for diagnostic
category, F (4, 114) = 25.46, p < 0.001. A Bonferroni post-hoc test revealed
patients diagnosed WNL and with a mood disorder had better scores than those
diagnosed with Alzheimer’s disease (p < 0.001; p < 0.001) and dementia other (p =
0.002; p < 0.001). Patients diagnosed with MCI performed better than those
diagnosed with Alzheimer’s disease (p < 0.001), and patients diagnosed with
Alzheimer’s disease performed significantly worse than those diagnosed with
dementia other (p = 0.016). See Table 32 for Rey-O immediate scaled score means.
Table 32. Rey-O immediate scaled scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
4
11
12
59
33

M
10.50
10.55
7.92
3.98
5.67

SD
3.11
4.34
2.27
1.42
2.86

df
4

F
p
25.46 <0.001

All other patients received a T-score for the Rey-O Immediate test and
analysis of these scores showed a significant difference for diagnostic category, F
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(4, 208) = 43.55, p < 0.001. A Bonferroni post-hoc test revealed patients diagnosed
as WNL performed better than patients diagnosed with MCI (p = 0.002),
Alzheimer’s disease (p < 0.001), and dementia other (p < 0.001). Patients
diagnosed with a mood disorder and MCI scored significantly better than patients
diagnosed with Alzheimer’s disease (p < 0.001; p < 0.001) and dementia other (p <
0.001; p < 0.001). See Table 33 for Rey-O immediate t-score means.
Table 33. Rey-O figure immediate t-scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
26
16
30
91
50

M
60.96
52.06
49.37
33.56
33.88

SD
13.57
18.28
12.44
9.15
9.67

df
4

F
p
43.55 <0.001

A subset of patients was given Rey-O Delay scaled scores which were
examined and there was a statistically significant difference for diagnostic
category, F (4, 112) = 25.35, p < 0.001. A Bonferroni post-hoc test revealed
patients diagnosed WNL, with a mood disorder, and MCI performed better than
those diagnosed with Alzheimer’s disease (p < 0.001; p < 0.001; p < 0.001) and
dementia other (p = 0.001; p < 0.001; p = 0.012). Finally, patients diagnosed with
Alzheimer’s disease performed worse than those diagnosed with dementia other (p
= 0.019). See Table 34 for Rey-O delay scaled score means.
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Table 34. Rey-O figure delay scaled scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
4
11
12
58
32

M
9.75
9.27
7.75
4.10
5.50

SD
3.40
1.65
2.30
1.42
2.31

df
4

F
p
25.35 <0.001

All other patients received a T-score for the Rey-O Delay test and analysis
of these scores showed a significant difference for diagnostic category, F (4, 204) =
45.37, p < 0.001. A Bonferroni post-hoc test revealed patients diagnosed as WNL
performed better than those diagnosed with MCI (p = 0.007), Alzheimer’s disease
(p < 0.001), and dementia other (p < 0.001). Patients diagnosed with a mood
disorder and MCI performed better than those diagnosed with Alzheimer’s disease
(p < 0.001; p < 0.001) and dementia other (p < 0.001; p < 0.001). See Table 35 for
Rey-O delay t-score means.
Table 35. Rey-O figure delay t- scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
26
16
30
88
49

M
61.23
48.19
46.40
29.72
31.73

SD
14.64
18.36
12.75
9.26
11.52

df
4

F
p
45.37 <0.001

Scores from the Shepherd Word List (delay, percent retention, recognition,
and commissions) were analyzed utilizing patient age and education as covariates.
For the word list delay score, there was found to be a significant difference for
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diagnostic category, F (4, 865) = 310.42, p < 0.001. Pairwise comparisons revealed
significant differences between all diagnostic categories. Patients diagnosed as
WNL performed significantly better than those diagnosed with a mood disorder (p
< 0.001), MCI (p < 0.001), Alzheimer’s disease (p < 0.001) and dementia other (p
< 0.001). Likewise, patients diagnosed with a mood disorder performed better than
those diagnosed with MCI (p < 0.001), Alzheimer’s disease (p < 0.001), and
dementia other (p < 0.001). Patients diagnosed with MCI performed significantly
better than those diagnosed with Alzheimer’s disease (p < 0.001) and dementia
other (p < 0.001). Finally, patients diagnosed with Alzheimer’s disease performed
significantly worse than those diagnosed with dementia other (p < 0.001). See
Table 36 for word list delay score means.
Table 36. Word list delay scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
308
193

M
7.24
6.05
4.35
1.00
2.26

SD
1.79
2.36
1.80
1.30
1.98

df
4

F
p
310.42 <0.001

Regarding the word list recognition scores, there was found to be a
significant difference for diagnostic category, F (4, 859) = 68.61, p < 0.001.
Pairwise comparisons revealed patients diagnosed WNL had better scores than
those diagnosed with MCI (p = 0.030), Alzheimer’s disease (p < 0.001), and
dementia other (p < 0.001). Also, patients diagnosed with a mood disorder and
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MCI had better scores than those diagnosed with Alzheimer’s disease (p < 0.001; p
< 0.001) and dementia other (p < 0.001; p < 0.001). Finally, patients diagnosed
with Alzheimer’s disease performed worse than those diagnosed with dementia
other (p < 0.001). See Table 37 for word list recognition score means.
Table 37. Word list recognition scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
302
193

M
9.35
8.94
8.57
6.05
7.04

SD
1.30
1.61
1.30
2.82
2.53

df
4

F
p
68.61 <0.001

Analysis of the number of word list commissions showed a significant
difference for diagnostic category, F (4, 858) = 29.65, p < 0.001. Pairwise
comparisons revealed patients diagnosed WNL, with a mood disorder, and MCI
performed significantly better than patients diagnosed with Alzheimer’s disease (p
< 0.001; p < 0.001; p < 0.001) and dementia other (p < 0.001; p < 0.001; p <
0.001). See Table 38 for word list commission score means.
Table 38. Word list commission scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
301
193

M
0.45
0.45
0.89
2.08
1.78

SD
1.32
0.84
1.11
2.06
1.81

df
4

F
p
29.65 <0.001
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Finally, word list retention was also recorded as a percentage of number of
delayed words out of the best number of words during the learning trial. For this
portion, there was a significant difference found for diagnostic category, F (4, 864)
= 193.57, p < 0.001. Pairwise comparisons revealed patients diagnosed as WNL
performed better than patients diagnosed with MCI (p < 0.001), Alzheimer’s
disease (p < 0.001), and dementia other (p < 0.001). Likewise, patients diagnosed
with a mood disorder performed better than those diagnosed with MCI (p < 0.001),
Alzheimer’s disease (p < 0.001), and dementia other (p < 0.001). Patients
diagnosed with MCI also performed better than patients diagnosed with
Alzheimer’s disease (p < 0.001) and dementia other (p < 0.001). Finally, patients
diagnosed with Alzheimer’s disease performed significantly worse than patients
diagnosed with dementia other (p < 0.001). See Table 39 for word list retention
percentage means.
Table 39. Word list retention percent scores
Diagnosis
WNL
Mood Disorder
MCI
Alzheimer’s disease
Dementia other

n
94
115
162
308
192

M
80.81
71.85
59.20
17.05
37.51

SD
16.57
24.48
21.25
22.04
31.04

df
4

F
p
193.57 <0.001

Initial Symptom Complaints
Patients’ chief symptom complaints and associated symptoms were
categorized based on first visit note. Memory loss was documented as the chief
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complaint for all but two patients (N = 981) whose initial symptoms were listed as
a mood disorder and lower extremity weakness. Out of all patients, most reported
two initial symptoms (N = 424) while a large majority only reported one (N = 348),
followed by three symptoms (N = 176), four symptoms (N = 32), and five
symptoms (N = 3). Refer to Table 40 for all frequencies and percentages of each
initial symptom.
Table 40. Initial Symptoms
Initial Symptom
Memory Loss
Mood
Sleep
Gait
Behavior
Psychotic
Tremor
Personality
Weakness

Frequency
981
430
189
143
58
35
26
4
1

Percent
52.5%
23.0%
10.1%
7.7%
3.1%
1.9%
1.4%
0.2%
0.1%

Because all but two of the chief complaints were memory loss, the
subsequent associated symptoms were analyzed using chi-squares to see if there
were any significant differences between initial symptoms and clinical diagnosis.
There was found to be a significant relationship between diagnosis and secondary
2
symptom complaint, X (24, N = 564) = 59.00, p < 0.001, where patients who
reported symptoms of a mood disorder were most likely to receive a clinical
diagnosis of a mood disorder. Patients who reported sleep disturbance were more
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likely to be diagnosed with WNL or dementia other. Patients who exhibited a
change in behavior, psychotic symptoms, or gait problems were more often
diagnosed with dementia other. Patients who displayed a tremor were more often
diagnosed with MCI or dementia other. Finally, patients with a personality change
were more often diagnosed with dementia other. See Table 41 for chi-square
relationships of secondary symptoms.
Table 41. Secondary symptoms and clinical diagnoses
Diagnosis
WNL

Mood

MCI

AD

Mood

Sleep

Psychotic

Gait

Tremor

Personality

3

2

6

1

0

N

31

%

57.4

20.4

5.6

3.7

11.1

1.9

0.0

N

85

10

0

0

2

2

0

%

85.9

10.1

0.0

0.0

2.0

2.0

0.0

N

57

14

2

1

13

2

1

%

63.3

15.6

2.2

1.1

14.4

2.2

1.1

N

120

20

14

7

20

2

0

%

65.6

10.9

7.7

3.8

10.9

1.1

0.0

70

14

15

10

24

3

2

50.7

10.1

10.9

7.2

17.4

2.2

1.4

Dem. other N
%

11

Behavior

There was also a significant relationship between diagnosis and tertiary
2
symptom complaint, X (20, N = 178) = 43.00, p = 0.002, where patients who
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reported symptoms of a mood disorder were most likely to receive a clinical
diagnosis of MCI. Patients who reported sleep disturbance were more likely to be
diagnosed with WNL or a mood disorder. Patients who exhibited a change in
behavior, psychotic symptoms, or tremor were more often diagnosed with dementia
other. See Table 42 for chi-square relationships of tertiary symptoms.
Table 42. Tertiary symptoms and clinical diagnoses
Diagnosis
WNL

Mood disorder

MCI

Mood

Sleep

N

2

14

0

1

6

0

%

8.7

60.9

0.0

4.3

26.1

0.0

N

2

21

0

1

10

1

%

5.7

60.0

0.0

2.9

28.6

2.9

N

4

18

1

0

4

2

%

13.8

62.1

3.4

0.0

13.8

6.9

3

21

4

3

11

0

%

7.1

50.0

9.5

7.1

26.2

0.0

N

3

11

8

5

13

9

%

6.1

22.4

16.3

10.2

26.5

18.4

Alzheimer’s disease N

Dementia other

Behavior

Psychotic

Gait

Tremor

88
Discussion
Analyzing the significant differences in individual testing scores by domain
assists in informing overall clinical diagnosis. By examining these differences over
time with a large sample, consistency of diagnoses based on previous findings can
be explored and refined if necessary. These studies become particularly important
as patient care and treatment plan relies heavily on differential diagnosis of
dementia, especially as this cohort continues to grow over the coming years.
After analyzing broad patterns of domains and diagnosis, it was found that
in the language domain, patients diagnosed WNL, with a mood disorder, or MCI
were more often categorized in the normal range, while patients diagnosed with
Alzheimer’s disease and dementia other were more often placed in the borderline
range.
Similar with attention and concentration, patients who were WNL, had a
mood disorder, or MCI were more often in the normal range, but patients who were
diagnosed with Alzheimer’s disease or dementia other were more often in the
impaired range.
Regarding executive functioning, patients diagnosed WNL or a mood
disorder were more often in the normal range, while those with MCI were in either
the normal or borderline range, and patients with Alzheimer’s disease and dementia
other were more often placed in the impaired range.
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Likewise, with the motor processing domain, patients diagnosed WNL and
a mood disorder were more likely in the normal range, while patients diagnosed
with MCI were mostly in the normal range, but starting to be placed more in the
borderline range, while patients diagnosed with Alzheimer’s disease and dementia
other were in the impaired range.
Interestingly, when it came to the visuospatial domain, patients diagnosed
WNL and with a mood disorder were in the normal range, those with MCI were
mostly in the normal range, some in the borderline range, while patients diagnosed
with dementia other were typically either in the borderline or impaired range.
Patients diagnosed with Alzheimer’s disease were mostly placed in the impaired
range. Finally, and as expected, patients diagnosed WNL and a mood disorder were
most often placed in the normal range, those with MCI were in the borderline
range, and patients diagnosed with Alzheimer’s disease and dementia other were
most often in the impaired range. This is a similar finding to past studies that have
found patients with Alzheimer’s disease to be most impaired in this domain (Reed
et al., 2007).
Because these broad patterns are based on individual scores within the
domain specific patterns of scores were examined by domain. It was unsurprising
to find that patients diagnosed WNL had performed the best on most tests.
However, there were some instances when scores were indistinguishable from other
diagnoses. For example, in the language domain, the MackSF4 score was not
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different from mood disorder or MCI. Also, the MAE sentence repetition score was
indistinguishable from all other diagnoses except Alzheimer’s disease. However,
this test is no longer used in the testing battery, so it’s inability to differentiate
between diagnoses is not an issue now. Other examples of indistinguishable scores
from mood disorder are the SDMT written score, CST response accuracy, and brief
Exit. As with the sentence repetition score, the CST response accuracy score in the
motor processing speed domain was indistinguishable from any other diagnosis and
is no longer used in the battery (due to the CST testing service being discontinued).
Finally, remaining scores that were statistically similar between WNL and mood
disorder were Rey-O copy scaled score and t-score, free clock, CST learning and
delay, word list recognition, word list commissions, and word list retention. The
Rey-O delay t-score and word list commission score was additionally
indistinguishable from an MCI diagnosis.
When it comes to a diagnosis of a mood disorder, it is important to note the
scores that separate this diagnosis from a diagnosis of WNL, as previous research
has shown that certain mood disorders, such as depression, can produce testing data
suggesting a neurocognitive disorder (Mukherjee & Rangasawami, 2014;
Chamberlain & Sahakian, 2006.) For example, in the language domain, patients
diagnosed with a mood disorder scored worse than those WNL on phonemic and
the phonemic/semantic split. These patients also scored lower than WNL on the
word list delay. Otherwise, patients diagnosed with a mood disorder performed at
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least better than those diagnosed with Alzheimer’s disease and dementia other,
while also scoring better than those diagnosed with MCI on the VST dots (motorprocessing speed) and CST response accuracy (executive functioning).
As might be expected, patients diagnosed with MCI tended to produce
scores that were lower than WNL and mood disorder, but higher than Alzheimer’s
disease and dementia other. However, certain scores were only better than patients
diagnosed with Alzheimer’s disease, such as the phonemic/semantic split
(language) and the Rey-O immediate scaled score (learning and memory).
Similar to previous research (Rogers, Ivanoiu, Patterson & Hodges, 2006),
patients diagnosed with Alzheimer’s disease most notably had the largest
phonemic/semantic split (language) compared to all other diagnoses. Other scores
in which patients diagnosed with Alzheimer’s disease scored the lowest out of any
other diagnosis were Rey-O immediate t-score and scaled score, word list delay,
word list recognition, and word list retention. Again, like previous research, it
appears that low scores in the learning and memory domain is what differentiates
Alzheimer’s disease from other diagnoses. However, is should be noted that there
were multiple scores in which those with Alzheimer’s disease were
indistinguishable from those diagnosed with dementia other. Examples of these
would be the MackSF4 (language), semantic, Trails B (attention and concentration;
executive functioning), SDMT oral, CST response accuracy, VST words, VST
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color, brief Exit, VST dots, free clock, copy clock, Rey-O copy, CST learning, CST
delay, Rey-O immediate t-score and Rey-O delay t-score.
Finally, the individual scores that separate dementia other from other
diagnoses based on lowest score were phonemic (language), Trails A, and SDMT
written (attention and concentration). Of course, this particular diagnostic category
is most difficult to analyze given the fact that it contains multiple difference
dementia diagnoses. However, the results of scores specifically from the attention
and concentration domain are somewhat in line with past research that has shown
Lewy body dementia (considered a “dementia other”) patients to be more impaired
in this domain (Ayre et al., 1998).
When examining the initial symptom complaints, it was unsurprising to find
the overwhelming majority of patients were given memory loss as chief complaint,
especially given that these patients are being referred to a memory disorder clinic,
specifically. It was also unsurprising that a large majority of patients who presented
with symptoms of mood disorders were ultimately diagnosed clinically with a
mood disorder following evaluation. However, since this symptom was the second
largest reported, the striking comorbidity of mood changes with dementia diagnosis
should also be noted. One interesting finding was that patients who reported sleep
difficulty were either diagnosed as cognitively normal or with dementia other. This
could depend largely on the specific type of sleep disorder, such as insomnia versus
REM sleep disorder, for instance, and leaves room for further refinement in future
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studies. The finding that behavior changes, psychotic symptoms, gait problems, and
tremors were more related to a dementia other diagnosis lines up with past research
that frontotemporal dementia is often associated with marked personality and
behavior change (Shinagawa, Ikeda, Fukuhara & Tanabe, 2006) and that Lewy
body dementia is characterized by well-formed visual hallucinations (Rongve,
Bronnick, Ballard & Aarsland, 2010) and Parkinson’s disease dementia has
movement problems as featured symptoms (Alzheimer’s Association, 2015).
A major strength of this study is the large number of patients available in
the database, along with the variety of different types of testing scores distributed
throughout each domain. Another strength is relative stability of testing measures
utilized over several years with only minimal changes made to the testing battery.
In fact, based on the statistical analyses, it appears the tests removed were weaker
in differentiating between diagnoses (i.e., MAE sentence repetition, CST response
speed). Another strength is the consistency of diagnosis based on specific patterns
of scores scrutinized by a treatment team which has a basis in previous, established
research. Another strength of this study is the revelation that despite using what is
considered a “brief” protocol, the patterns of scores and results were similar to
previous research utilizing a full battery.
The prominent limitation of this study is the lack of neuropathological
findings that would confirm the clinical diagnosis to truly know how closely the
score patterns predict an accurate diagnosis. While the Florida Brain Bank Program
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maintains a database of neuropathological findings, unfortunately it not easily
accessed for the purpose of research projects. Another limitation is the inability to
distinguish certain dementia diagnoses grouped together into one “dementia other”
category because of low numbers of patients within such categories (i.e., Lewy
body dementia, frontotemporal dementia). In order to truly differentiate all
categories, it would be necessary to isolate these and perform separate analyses.
Another similar limitation is a marked overlap in test scores and domains that can
take away from the specificity of scores. This is most apparent with several test
results that are statistically the same between Alzheimer’s disease and dementia
other, making it more difficult to distinguish between these diagnostic categories.
Finally, a limitation relates specifically to the CST scores given that this is a test no
longer available for clinical use. Therefore, there is no way to use this test for
future data collection.
There were some limitations related specifically to gathering data for initial
symptoms complaints. For example, there does not appear to be a standardized
form for asking patients about these specific symptoms and patients have seen
different providers for their initial appointment who likely have varying ways of
obtaining information. Therefore, providers may not specifically ask patients about
certain associated symptoms. Another limitation is the high comorbidity of
symptom complaints which makes it difficult to distinguish which is more
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prominent. For example, a sleep disorder may be secondary to a mood disorder and
not necessarily a symptom of dementia.
Future research should take these limitations into consideration and more
focus placed on the importance of data gathered by brain banks where
neuropathological reports can provide accurate dementia diagnoses to be compared
to clinical diagnoses. This would be the only way to truly ensure the ability of
neuropsychological testing to more accurately predict clinical diagnoses. Because
most patients who enter a memory disorder clinic are given a chief complaint of
memory loss, perhaps more importance should be placed on delving into all
associated symptoms in order to assist in early differentiation between Alzheimer’s
disease and other types of dementia. Overall, these studies need to continue to be
carried out since the more precise a clinical diagnosis is made, the better a
treatment plan and resources can be provided for the patient to address their
specific needs, which would in turn improve quality of life. This outcome is often
the best to strive for with incurable, degenerative diseases. Until medical treatments
make tremendous improvements, accurate diagnostics can go a long way in
assisting patients, especially when the population in question is continuing to grow
along with the need for best treatment.
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APPENDIX: Neuropsychological Measures and Descriptions

1. Controlled Oral Word Association Test (COWAT): A subtest of the
Multilingual Aphasia Examination battery involving spontaneous
production of words under restricted search conditions for both phonemic
and semantic fluency tasks.
2. Multilingual Aphasia Examination (MAE) Sentence Repetition: A subtest of
the MAE battery that requires the repetition of 14 sentences of increasing
length up to 22 syllables. Vocabulary and syntax are deliberately simple,
but interrogative, negative, and other forms are included.
3. Trail Making Test A and B: A test of visual attention and task switching
consisting of two parts. Part A involves connecting a set of 25 dots as
quickly as possible while maintaining accuracy, and part B requires the
subject to alternate between numbers and letters in sequential order.
4. Symbol Digit Modalities Test (SDMT): A test used to assess divided
attention, visual scanning, tracking, and motor speed.
5. Cognitive Screening Test (CST): A computerized test designed to measure
response inhibition, fine motor skills and processing speed, visual learning
and encoding, and delayed recall for visually presented stimuli.
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6. Victoria Stroop Test: A measure of cognitive control that assesses the ease
with which a person can maintain a goal in mind and suppress a habitual
response in favor of a less familiar one.
7. Clock Drawing Test: A test measuring visual-spatial constructional ability
(free) and delineates executive difficulties from visual-constructive deficits
(copy).
8. Shepherd Serial List Learning Test: A measure of verbal learning and
encoding along with delayed recall for verbal information. The recognition
portion determines recognition of words presented in an array of distractor
words.
9. Executive Interview (EXIT – Brief Edition): A screening measure designed
to measure overall executive function.
10. MackSF4: A brief test of confrontational naming based on the full version
of the Boston Naming Test.
11. Rey-Osterrieth Complex Figure test (Rey-O): A test to assess visual-spatial
constructional ability and visual memory.

